Clinical

Editor in Chief

N. Zöl lner, Munich

Editorial Board H.B. Stähel in, Basle Mainz

G. Adler, Ulm K.-H. Usadel , Frankfurt a.M. M J . Mihatsch, Basle Μ.Ε. Bertrand, Li l le G. Vantrappen, Louvain B.S. Mitchel l , Chapel Hill Τ. Brandt, Munich P. von Wiehert, Marburg O.-A. Mül ler, Munich Ε. Erdmann, Munich K.G. Wormsley, Dundee J.G. Puig, Madr id W. Gerok, Freiburg E.O. Riecken, Berl in G. Giebisch, New Haven E. Ritz, Heidelberg F.-D. Goebel, Munich D. Häussinger, Freiburg

Advisory Board R. Ritz, Basle S. Sacks, London

H. Kaess, Munich R. Arno ld , Marburg H. Schuster, Munich J.R. Kalden, Erlangen W.G. Daniel , Hannover Η.-P. Schuster, Hi ldesheim G.J. Krejs, Graz A. Dist ler, Ber l in W. Seeger, Glessen W. Kubier, Heidelberg H.L. Fehm, Lübeck H.-G. Sieberth, Aachen H. Loftier, Kiel R. Ferl inz, Mainz F.-A. Spengel , Munich J. Lubsen, Rotterdam 0 . Götze, Gött ingen G. Steinbeck, Munich P.M. Mannucci , Mi lan F.A. Gr ies, Düsseldorf J.A. Tischf ie ld, Indianapol is P.A. Miescher, Geneva W.L. Gross, G. Utermann, Innsbruck G. Paumgartner, Munich Lübeck/Bad Bramstedt H. Vetter, Bonn H.D. Pohle, Ber l in E.G. Hahn, Er langen C. Wagener, Hamburg D.L. Scott, London H.-L. Hahn, Wiesbaden M. Wienbeck, Augsburg P.C. Scriba, Munich D. Hoelzer, Frankfurt a.M. G. Wolfram, Munich D. Seidel, Munich C. Kel ler, Munich R. Ziegler, Heidelberg G. Seifert, Hamburg H.J. Kramer , Bonn

w v ^ | 3 r ' n ^ e r ' n t e r n a t ' o n a '

A c

Clinical Investigator

Aims and scope Original papers and reviews in all fields of clinical research will be published. Reviews com­patible with the specialist sec­tions of the journal or editorials commenting on original articles are particularly welcome. The publication of rapid communica­tions describing significant new findings will be given priority. Specialist sections linking basic research and clinical investiga­tion will include: — Molecular medicine — Clinical pharmacology The Editors also encourage the submission of: — Case reports — Correspondence — Book reviews — Relevant news items — Letter(s) to the editors To ensure the widest possible readership, only manuscripts in English will be considered. Ei­ther British or American usage is permitted, provided the usage is internally consistent.

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been examined by the appropri­ate ethics committee and have therefore been performed in accordance with the ethical stan­dards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed con­sent prior to their inclusion in the study. De­tails that might disclose the identity of the sub­jects under study should be omitted.

Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were fol­lowed, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable.

The editors reserve the right to reject manu­scripts that do not comply with the above-men­tioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication else­where; that its publication has been approved by all coauthors, if any, as well as by the re­sponsible authorities at the institute where the work has been carr ied out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copy­right holders.

All articles published in this journal are pro­tected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfi lm, in electronic data bases, video disks, etc., without first obtaining written per­mission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not im­ply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no war­ranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or in-house use beyond the limitations stipulat­ed under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0941-0198, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distr ibution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

The Canada Institute for Scientific and Techni­cal Information (CISTI) provides a comprehen­sive, world-wide document delivery service for all Springer-Verlag journals. For more informa­tion, or to place an order for a copyright-cleared Springer-Verlag document, please contact Client Assistant, Document Delivery, Canada Institute for Scientific and Technical Information, Ottawa K1A 0S2, Canada (Tel: 613-993-9251; Fax: 613-952-8243; e-mail : cisti.docdek" nrc.ca).

ADONIS This journal is included in the ADONIS service, whereby copies of individual articles can be printed out from compact discs (CD-ROM) on demand. An explanatory leaflet giving further details of the scheme is available from the publishers on request.

Subscription Information Volume 72 (12 issues) will appear in 1994.

North America: Recommended annual sub­scription rate: approx. US $ 417.00 (single is­sue price: approx. US $ 40.00) including car-riagecharges.Subscriptionsareentered with pre­payment only. Orders should be addressed to: Springer-Verlag New York Inc. Journal Fulfillment Services Dept 333 Meadowlands Parkway Secaucus, NJ 07094, USA Tel. (201) 348-4033, FAX (201) 348-4505

All other countries: Recommended annual sub­scription rate: DM 586.00 plus carriage charges; [Germany: DM 43.80 incl. value added tax; all other countries: DM 57.00, ex­cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan, India, Australia New Zealand. SAL charges and airmail delivery to all other coun­tries are available upon request]. Volume price: DM 586.00, single issue price: DM 58.60 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3 D-14197 Berl in, Germany Tel. (0) 30/8207-0, FAX (0) 30/8214091

Cancellations must be received by September 30 to take effect at the end of the same year.

Changes of address: Allow six weeks for all changes to become effective. All communica­tions should include both old and new address­es (with postal codes) and should be accompa­nied by a mailing label from a recent issue. According to §4 section 3 of the German Postal Services Data Protection Regulations, the German Federal Post Office can inform the publisher of a subscriber's new address even if the subscriber has not submitted a formal application for mail to be forwarded. Subscribers not in agreement with this proce­dure may send a written complaint to Springer-Verlag's Berl in office within 14 days of publica­tion of this issue.

Black volumes: Prices are available on request.

Microform Microform editions are available f rom: University Microfilms International 300 N. Zeeb Road, Ann Arbor, Ml 48106, USA

Production Springer-Verlag, Beate Uhl Journal Production Department II Postfach 105280 D-69042 Heidelberg, Germany Tel. (0) 6221/487-554, FAX (0) 6221,487625 e-mai l : uh\(a springer.de

Responsible for advertisements E. Lückermann, Springer-Verlag Heidelberger Platz 3 D-14197 Berl in, Germany Tel. (0) 30/8207-0, FAX (0) 30/8207300

Printers Universitätsdruckerei Η. Stürtz AG, Würzburg © Springer-Verlag Berlin Heidelberg 1994 Springer-Verlag GmbH & Co. KG D-14197 Berl in Germany

Printed in Germany

Contents of Volume 72 No 1: PP 1 - 84 publ ished December 6, 1993 No 2: PP 8 5 - 166 publ ished January 31 , 1994 No 3: PP 167- 250 publ ished February 28, 1994 No 4: PP 2 5 1 - 330 publ ished March 31 , 1994 No 5: PP 3 3 1 - 414 publ ished May 6, 1994 No 6: PP 4 1 5 - 480 publ ished June 23, 1994 No 7: PP 4 8 1 - 554 publ ished July 26, 1994 No 8: PP 555 - 638 publ ished August 30, 1994 No 9: PP 639 - 730 publ ished September 19, 1994 No 10: PP 7 3 1 - 814 publ ished October 19, 1994 No 1 1 : PP 8 1 5 - 936 publ ished November 2, 1994 No 12: PP 937-" 1098 publ ished December 16, 1994

Supplement to Volume 72/lssue 6: Erythropoiet in and Auto logous Transfusion, Dresden, September 14-18, 1993

Abe Κ - * Mizunashi Κ Aboudan F -> Evers J Ackermann Μ -* Krämer BK Adamek RJ, Wegener M, Wienbeck Μ, Köh­

ler Η, Hoffmann Κ, A l tmeyer Ρ: Long-term manomet ry of tubular esophagus in progress ive systemic sclerosis 343

Adams Ο -> Jablonowski Η Adlkofer F -» Einhaus Μ Adorf D, Gra jer KH, Kaboth W, Neri C:

Agranulocytos is induced by ant i thyroid therapy: effects of t reatment with g ranu­locyte colony st imulat ing factor 390

Agnati LF -> Fuxe Κ A g u i l a r M Gomez JM Ahmad Μ - * Syed TA Ahmad SA -> Syed TA Albert i Β -»· Antonel l i A Albrecht Η Stel lbr ink HJ Albrecht Η, Stel lbr ink HJ, Gross G, Berg B,

Helmchen U, M e n s i n g H : Treatment of atypical le ishmanias is wi th interferon γ resul t ing in progress ion of Kaposi 's sar­coma in an AIDS patient 1041

Alexander Κ -> Ranke C A l le rberger F -> Vogetseder W Al tmeyer Ρ -> Adamek RJ Andbjer Β -> Fuxe Κ Andresen D -»· Behrens S Angermann CE -> Stempfle HU Antonel l i A, Campatel l i A, Di Vito A, Alber-

ti B, Ba ld iV, Salv ioni G, Fallahi P, Ba-schier i L: Compar ison between ethanol sc lerotherapy and empty ing with injec­t ion of sa l ine in t reatment of thyro id cysts 971

Anzai Κ -» Nagafuchi S Arno ld JC, Hei l ig Β, Kal l inowski Β, Otto G,

Kommere i l Β, T h e i l m a n n L : Soluble tumor necrosis factor receptors in patients wi th recurrent hepatit is C v i ­rus infect ion after l iver t ransplantat ion 470

Atzpodien J -+ Buer J Auberger Κ -> Wintergerst U Aufenanger J - • Ensenauer R Avenar ius H-J -> Ranke C

Baart de la Fail le Η Lupus therapy 749 Bacher Β Wang Χ

Bäcker A Bokemeyer D Bäcker A -> Kramer HJ Bajo A -> Laso FJ B a k k e r C J G : Magnet ic resonance angiog­

raphy 85 Baldauf J -> Jurna I Baldi V Antonel l i A B a l d u s M , Möl ler M, Walter H, Brass H,

Q u e i ß e r W : A case of pure red cell ap las ia : fo l low-up on different immuno­suppressive reg imens 1051

Balfour DJK - * Benwel l MEM Banyai Μ -> Capek Μ Barash V -> Chajek-Shaul Τ Bartens W, Wanner C: L ipoprote in(a) : new

insights into an atherogenic l ipoprotein 558

Bar tmann Ρ -> Jab lonowsk i Η Baschier i L -> Antonelli A Base W -> Sexl V Bauer J, Hohagen F, EbertT, T immer J,

Ganter U, Kr ieger S, Lis S, Postler E, Voderholzer U, B e r g e r M : lnterleukin-6 serum levels in healthy persons corre­spond to the s leep-wake cycle 315

Bauer Τ -> Hagendorff A Baumgar tner G - * Pecherstorfer Μ Bayraktar M, Usman A, Koray Z : Effect of

the new somatostat in analogue SMS 201-995 on exogenously used in­sul in 669

Becher Η -> Schmitz U Beger Η ->· L immer J Behrens S, Andresen D, Brüggemann Τ,

Schröder R: Ventr icular f ibr i l lat ion relat­ed to coronary spasm in patients wi thout s igni f icant coronary or other structural heart d isease 307

Behr R Füssle R BehrT, Fischer P, Mül ler-Felber W,

Schmidt-Achert M, Pong ra t zD : Myofi-br i l logenesis in pr imary t issue cultures of adult human skeletal musc le : expres­sion of desmin , t i t in, and nebul in 150

Belohradsky BH -» Wintergerst U Benker G -> Jaspers C Benwel l MEM, Balfour DJK, Khadra LF:

Studies on the inf luence of nicotine infu­sions on mesol imbic dopamine and lo­comotor responses to nicotine 233

Berg Β -> Albrecht Η Berger Μ -> Bauer J Bergmann L -> Kamps BS Berg PA -> Klein R Bergs C -+ Schneider Τ Bernecker Ρ -> Erlacher L Besenthal I Knisei W Beyenburg S -* Schröder R Beyer J Kubier A Bingley PJ -> Wagner R Biscoping J -+ Füssle R Bittl Μ -> Br iegel J Blaustein MP: Endogenous ouaba in : phy­

siological activity and pathophysio logi­cal impl icat ions 706

Bleich Μ -> Greger R Blum HE -> Offensperger W-B Bobrow Μ -+ Flinter F Bode-Böger S -»· Ranke C Bodmann KF, Tröster S, Clemens R, Schu­

ster HP: Hemodynamic profi le of intra­venous fenoldopam in patients with hy­pertensive cr isis 60

Boehme MWJ, Werle E, Kommere l l B, Raeth U: Serum levels of adhesion mo­lecules and thrombomodul in as indica­tors of vascular injury in severe Plas­modium fa lc iparum malar ia 598

Bogner C Gawaz Μ Bogner JR Liegl U Bogner JR Rolinski Β Böhmer Β -» Malessa R Bokemeyer D Kramer HJ Bokemeyer D, Fr iedr ichs U, Bäcker A,

Kramer HJ, Meyer-Lehnert H: Cyclospo-rine A enhances total cell calc ium inde­pendent of Na-K-ATPase in vascular smooth muscle cel ls 992

Böke rKHW -> Mül ler MJ Boldt I -> Brennemann W Bonifacio Ε -> Wagner R Bonmann Ε Witzke Ο Borberg Η ->· Waidner Τ Borensztein Ρ -> Pinet F Borräs R -> Laso FJ Bottazzo GF -> Wagner R Boye Ε Flinter F Brandl BC -> Stempfle HU Brass Η -> Baldus Μ Braun GG Tschaikowsky Κ Brech W -> Murer Η Brennemann W, Brensing ΚΑ, Leipner Ν,

Boldt I, K l ingmül ler D: Attempted pro­tection of spermatogenesis f rom i r radia­t ion in patients with seminoma by D-Tryptophan-6 luteinizing hormone re­leasing hormone 838

Brensing KA -»• Brennemann W Breyer S -> Wenisch C Brezinschek HP -> Wascher TC Brezinschek R -> Wäscher TC Br iegel J , Kel lermann W, Forst Η, Haller

Μ, Bittl Μ, Hoffmann GE, Büchler Μ, Uhl W, Peter Κ, Phosphol ipase A 2 Study Group: Low-dose hydrocort isone infu­sion attenuates the systemic in f lamma­tory response syndrome 782

Brockmeyer NH -> Malessa R Brockmöl ler J Drakou l i sN Brodt H-R -> Kamps BS Brown D -> Sabolic I

IV

Brückmann C -* Wintergerst U Brüggemann Τ -> Behrens S Brunkhorst R, Wrenger E, Koch K M : Low-

dose predniso lone/ch lorambuci l thera­py in patients wi th severe membranous g lomerulonephr i t is 277

Büchler Μ -> Br iegel J B u e r J , Kirchner Η, Schomburg Α, Schü­

ler A, Manns Μ, Lopez-Hänninen Ε, Duensing S, Pol iwoda Η, Atzpodien J : Cytokine-based biotherapy of gastro­intestinal tumors 526

Butruk Ε -> Habior A Butz Κ -> Hoppe-Seyler F B y e S , Mal lmann R, D u l e y J , S im-

monds HA, Chen J, Tischf ield JA, Sa-h o t a A : Identif ication of a 7-basepair delet ion in the adenine phosphor ibosy l -t ransferase gene as a cause of 2,8-dihy-droxyadenine urol i th iasis 550

Caine Y - • Chajek-Shaul Τ Calzetti C Pedretti G Campatel l i A - * Antonel l i A Canessa C -> Hor isberger J-D Capek M, Schnack C, Ludvik B, Kautzky-

Wi l l e rA , Banyai M, Prager R: Effects of Captopril treatment versus placebo on renal function in type 2 diabet ic patients with microa lbuminur ia : a long-term study 961

Cascorbi I - > Drakoul is Ν Caspary WF -> Wehrmann Τ Castro de S -> Laso FJ Chajek-Shaul T, Scherer G, Barash V, Shi -

loni E, Caine Y, Stein O, Stein Y: Meta­bolic effects of nicotine on human adipose t issue in organ culture 94

Cheema KM -> Syed TA Cheema R -> Syed TA Chen J - * Bye S Christ M, Klauss V, Pl iml W, Theisen K,

W e h l i n g M : Volumes and N a + / H 4 an-t iporter activity of lymphocytes in pa­tients with congest ive heart fa i lure 985

Chuman Η -» Nagafuchi S Cissewski Κ - * Rzepka AH Classen H-G Rob PM Clemens R -> Bodmann KF Cocozza S -> De Lorenzo F Co l lazosJ , Mart inez E, Flores M, M a y o J :

Aspergi l lus pneumonia successful ly treated with i t raconazole in a patient with systemic lupus erythematosus 920

Collazos J : Glycochol ic acid in chronic ac­tive hepatit is and mi ld l iver diseases 36

Collet C Lingenfelser Τ Cordero Μ -> Laso FJ Corvol Ρ - • Pinet F Creutzig A -> Ranke C

Danek A, Witt TN, Mann K, Schweikert HU, Romalo G, La Spada AR, Fischbeck K H : Decrease in androgen binding and ef­fect of androgen treatment in a case of X-l inked bulbospinal neuronopathy 892

Danos Ρ -> Hagendorff A Danpure CJ : Molecular and cell biology of

pr imary hyperoxalur ia type 1 725 Decrinis M, Doder S, Stark G, Pilger E: A

prospective evaluat ion of sensit ivi ty and

specif icity of the ank le /brachia l index in the fo l low-up of superf ic ia l femora l artery occlusions t reated by angiop las­ty 592

Dell ing G Harten Ρ De Lorenzo F, Mont icel l i A, Cocozza S,

De Simone Β, Rubba Ρ: Ext racoronary atherosclerosis and genet ic var iants of apol ipoprote in AI-CIII c luster in myocar­dial infarct ion surv ivors f rom southern Italy 435

Denislic M, Meh D: N e u r o p h y s i o l o g y as­sessment of per iphera l neuropathy in pr imary Sjogren 's syndrome 822

De Simone Β -> De Lorenzo F Deitmers C -+ Hagendorff A DeVries JX -> Sch lenke rT Dieckmann K-P -> Gross AJ Diener H-C -> Malessa R Dienes HP - Wölfel Τ Dierich MP - • Vogetseder W Dih lmannW, Schnabel A, Gross WL: The

acquired hyperostosis synd rome: a l i tt le known skeletal d isorder wi th dist inct ive radiological and c l in ical features 4

Dippold W - Wölfel Τ Dirksen U -+ Horneff G Dissmann Τ -> Schneider Τ Di Vito A Antonel l i A DobmeyerJ - * Feussner G Dobos GJ, Traynor-Kaplan AE, Ward D,

Schol lmeyer PJ: Neutrophi l dysfunct ion in end-stage renal fa i lu re : reduced re­sponse to pr iming by C5a 353

Doder S ->· Decrinis Μ Doherty Ε Seed Μ Dörr U -> Iser G Drakoul is Ν, Cascorbi I, Brockmöl ler J,

Gross CR, Roots I: Po lymorph isms in the human CYP1A1 gene as suscept ib i l i ­ty factors for lung cancer : exon-7 muta­tion (4889 A to G), and a Τ to C mutat ion in the 3'-f lanking region 240

Drexel Η -> Föger Β Duensing S -> Buer J Du leyJ -> B y e S Duque-Reina D -> Mertens PR Düsing R -> Schmitz U Düsing R, Le ibhammer S, Hoffmann G,

Vetter Η, Siffert W: Hypertonic sal ine in­fusion induces act ivat ion of the lympho­cyte Na + / H + ant iport and cytosol ic a lka-l inization in healthy human subjects 817

Eber tT -» Bauer J Eber tW - Muley Τ Eckert F -> Wagner DR Eggstein Μ -> Knisei W Eggstein Μ -> Lingenfelser Τ Eggstein Μ -> Luft D Ehmke Η -> Ki rchheim HR Ehrenreich Η -> Rolinski Β Ehrenreich Η, Poser W: Dependence on

tramadol 76 Ehrl ich S -> Haak Τ Eiben Ρ -> Sander D Einhaus M, Holz O, Meißner R, Krause T,

Warncke K, Held I, Scherer G, Trick­er AR, Adlkofer F, Rüdiger HW: Determi­nation of DNA single-strand breaks in

lymphocytes of smokers and nonsmok-ers exposed to env i ronmenta l tobacco smoke using the nick t ranslat ion assay 930

Eisele Ε -> L immer J Elia G -> Pedrett i G Ellbrück D -> L immer J Endo Κ -> Mizunashi Κ Endres HGE, Grüner Ο: Compar ison of

D 2 0 and ethanol di lut ions in total body water measurements in humans 830

Engelhardt D: Steroid biosynthesis in­hibi tors in Cushing's syndrome 481

Engelstein Ε, Terres W, Hofmann D, Han­sen L, Hamm CW: Improved g lobal and regional left vert icular funct ion after an­gioplasty for chronic coronary occ lu­s ion 442

Ensenauer R, Püttmann Μ, Quintel Μ, Kat-te rmann R, A u f e n a n g e r J : Compar ison of serum phosphol ipase A 2 , po lymor­phonuclear granulocyte elastase, C-re-act ive protein and serum amylo id A with the APACHE II score in the prognosis of mul t ip le in jured patients 843

Erdmenger L -> Jeck Τ Er lacher L, Teufelsbauer Η, Bernecker Ρ,

Pietschmann Ρ, Weissei Μ: Compar ison of serum f luor ide levels after admin is ­trat ion of monof luorophosphate-ca lc ium carbonate or sodium f luor ide : differ­ences in peak serum concentrat ions 1082

Escobar-J imenez F -> Vidal-Puig A Etzersdorf er Ε -> Wenisch C Euler HH -> Harten Ρ European Working Group on Famil ia l Hy­

p e r c h o l e s t e r o l e m i a -> Schuster Η Evers J , Aboudan F, Lewalter J, Renner Ε:

Hemodia lys is in metacresol po ison ing 472

Ewers-Grabow U -> Windler Ε

Fabel Η -» Flüge Τ Faergeman Ο -> Hansen PS Fallahi Ρ -> Antonel l i A Falter Β, Kutzer C, Richter Ε: B iomoni tor ­

ing of hemoglob in adducts : aromat ic amines and tobacco-specif ic ni tro-samines 364

Fandrey J -> Gross AJ Fehske W -» Reichel W Feldges A Korte W Ferl inz R Kienast Κ Ferl inz R -> Lorenz J Femandez-Castaner Μ -> Fernandez-Re­

al JM Fernandez Castaher Μ -> Gomez Säez JM Fernandez Real JM -»· Gomez Säez J M Fernändez-Real JM, Fernandez-Cas­

taner M, V i l l abonaC, Sagarra E, Go-mez-Säez JM, Soler J : Giant in t rasel lar aneurysm present ing with panhypopi tu­i tar ism and subarachnoid hemor rhage : case report and l i terature review 302

Feussner G, Stech C, D o b m e y e r J , Schae-fer H, Otto G, Ziegler R: Serum amy lo id A protein (SAA): a marker for l iver a l lo­graft reject ion in humans 1007

Fiaccadori F -> Pedrett i G Fil le Μ Vogetseder W

ν

Finnman U-B Fuxe Κ Fischbeck KH -> Danek A Fischer A, König W: Modulat ion of in v i t ro

Immunoglobul in synthesis of human pe­r ipheral b lood mononuc lear cel ls by nicotine and cot in ine 225

Fischer HP -+ Reichel W Fischer Μ -» Pecherstorfer Μ Fischer Ρ -> Behr Τ F l e s c h M , Sachin id is A, Ko YD, Kraft Κ,

Vetter Η: P lasma l ipids and l ipoprote ins and essent ial hyper tension 944

Flik J Wagner D F l in terF, Boye E, Vetrie D, Harr is A, Bo-

brow Μ: Genetic aspects of renal dys­funct ion: A lpor t 's syndrome 728

F l i se rD , R i t z E : Cl in ical prob lems of d i ­uretic t reatment 708

Flores Μ -» Col lazos J Flüge T, Fabel Η, Wagner TOF, Forss-

m a n n W G : Local izat ion of the bron-chodi lator effect induced by type A natr i ­uretic peptide in asthmatic subjects 772

Flury RF -> Risti Β Föger Β, Drexel Η, Hopferwieser Τ, Mie­

senböck G, Ritsch A, Lechlei tner M, T röb inge rG, Patsch JR: Fenofibrate im­proves postprandia l chy lomicron clear­ance in II Β hyper l ipoprote inemia 294

Fölsch Β -» Haiwachs G Fölsch UR -> Mönig Η Forssmann WG -> Flüge Τ Forst Η -> Br iegel J Franzen D -> Waidner Τ Frei U Kl iem V F r e y F J : 11 ß-Hydroxysteroid dehydroge­

nase: a re levant determinant of g luco-and mineralocor t ico id-act ions 701

Fr iedberg Τ -> Lorenz J Friedrichs U —> Bokemeyer D Fritsch Η -> Ju l ius U Fritsch W -> Ju l ius U Fröl ich J --> Ranke C Fuchs S -* Pinet F Fücker Κ -»> Ju l ius U Fukushima Ν -*• Nagafuchi S FurukawaY -» Mizunashi Κ Füssle R, Biscoping J, Behr R, Sziego-

leit A: Development of resistance by En­terobacter c loacae dur ing therapy of pulmonary infections in intensive care patients 1015

Fuxe K, Rosen L, Lippoldt A, Andbjer B, Hasselrot U, F innman U-B, Agnat i LF : Chronic cont inuous infusion of nicot ine increases the d isappearance of chol ine acetyl t ransferase immunoreact iv i ty in the chol inergic cel l bodies of the media l septal nucleus fo l lowing a part ial uni lat­eral t ransect ion of the f imbr ia fornix 262

Galanski Μ -» Ranke C Gamba G -> Hebert SC Gandenberger S -> Wintergerst U Ganter U -> Bauer J Garcia-Calvente C -» Vidal-Puig A Garcia-Sänchez JE -> Laso FJ Gärtner HV Spyr idopoulos I Gawaz M, Bogner C: Changes in platelet

membrane g lycoprote ins and platelet-

leukocyte interact ion dur ing hemodialy­sis 424

Geier SA -» Rol inski Β Genovese S - * Wagner R Gerdes LU Hansen PS Gerken G -> Wölfel Τ Germain S -+ Pinet F German AIDS Study Group : Survival of pa­

tients receiv ing z idovudine before or af­ter AIDS d iagnos is : results of a German mult icenter study 111

Gerok W Hafkemeyer Ρ Gerok W -»· Offensperger W-B Glaser F - • Wolf Ο Goebel FD -» Liegl U Goebel FD -» Rol inski Β Goebel Y -> Rob PM Gomez JM, A g u i l a r M , Navarro MA, Orto-

l ä J , S o l e r J : Secret ion of growth hor­mone and thyroid-st imulat ing hormone in patients wi th dement ia 489

Gomez-Säez JM -> Fernändez-Real JM Gomez Säez JM, Fernandez Real JM, Fer­

nandez Castaner M, Navarro Moreno MA, Mart inez Matos JA: Study on growth hormone and insul in secret ion in myotonic dystrophy 508

Gonzälez-Bui t rago JM Laso FJ Grabensee Β -> Hol lenbeck Μ Grabitz Κ -» Kniemeyer HW Grajer KH Adorf D Graninger W -> Wenisch C Greger R, Lohrmann E, Bleich M: Tubular

act ions of d iuret ics (overview) 690 Greminger P, Suter PM, Holm D, Kobelt R,

Vetter W: Morn ing versus evening ad­ministrat ion of ni fedipine gastrointest i ­nal therapeut ic system in the manage­ment of essent ial hypertension 864

Gresser U -+ Wagner DR Gressner AM -> Körner Τ Greten Η -> Stel lbr ink HJ Greten Η -> Windler Ε G r i g o r i e v A l , Morukov BV, Vorob ievDV:

Water and electrolyte studies dur ing long-term missions onboard the space stat ions SALYUT and MIR 169

Gross AJ, Wolff M, Fandrey J , Miersch W-D, Dieckmann K-P, Je lkmann W: Preva­lence of paraneoplast ic erythropoiet in product ion by renal cell carc inomas 337

Gross CR -> Drakoul is Ν Gross G -+ Albrecht Η Gross W - * Haak Τ Gross WL -> D ih lmannW Grüner Ο -> Endres HGE Grünert A -» Haug C Grüne S Jeck Τ Gwechenberger Μ ->· Hirschl MM

Haak T, Jungmann E, Kasper-Dahm G, Ehrl ich S, Usadel K H : Elevated endothe­lin 1 levels in cr i t ical i l lness 214

HaakT, MärzW, Jungmann Ε, Hausser S, Siekmeier R, Gross W, Usadel K-Η: Ele­vated endothel in levels in patients with hyper l ipoprote inemia 580

Habenicht AJR, Janßen-Timmen U, Z ieg­ler R, Schett ler G: Lipoproteins and their funct ions 639

Habior Α, Walewska-Zielecka Β, Butruk Ε: Hepatocel lular-cholestat ic l iver injury due to amoxyci l l in-c lavulanic acid com­bination 616

Haferkamp Ο, Seibold Η, Stauch Μ, Klee­berg S, Rödel G: Neutrophi l ic migrat ion through capi l lary l ike mic ropores : inf lu­ence of pu lmonary passage 30

Hafkemeyer P, Schupp Μ, Storch Μ, Ge­rok W, Häussinger D: Excessive iron storage in a patient wi th Wilson's dis­ease 134

Hagendorff A, Deitmers C, Danos P, Wet­ter S, Lassau M, Pizzull i L, Omran H, Bauer T, Hartmann Α, Lüderitz Β: Carot­id artery stenosis and tachyarrhythmi­as : regional cerebral blood f low dur ing high-rate ventr icular pacing after one vessel occlusion in rats 775

Hake U H e r r W H a l b m a y e r W M -> Pecherstorfer Μ Hal ler Μ -> Briegel J Haiwachs G, Tiran A, Reisinger EC, Zach

R, Sabin Κ, Fölsch Β, Lanzer Η, Holz­er Η, Wilders-Truschnig Μ: Serum lev­els of the soluble receptor for tumor ne­crosis factor in patients with renal d is­ease 473

H a m m a r C - H - * Körner Τ Hamm CW -> Engelstein Ε Hammel G -> Schewe CK Hanefeld Μ -> Jul ius U Hanke Η -> Strohschneider Τ Hannekum A -> Strohschneider Τ Hansen L -> Engelstein Ε Hansen PS, Me ine r t zH , Gerdes LU, Klau­

sen IC, Faergeman O: Treatment of pa­tients with fami l ia l defective apol ipo-protein B-100 with pravastatin and gem­f ib roz i l : a two-per iod cross-over study 1065

Harr is A -> Flinter F Harr ison-Bernard LM -> Navar LG Harten P, Euler HH, Wolf E, Dell ing G,

Lö f f l e rH : Disseminated histoplasmosis in a non- immunocompromised host 878

Hart lapp JH Reichel W Hartmann A -> Hagendorff A Hashizume Μ Nagafuchi S Hassel rot U Fuxe Κ Hatano A -> Takeda Μ Haug C, Metzele Α, Stetigen J, Kochs Μ,

Hombach V, Grünert A : Increased brain natr iuret ic peptide and atr ial natr iuret ic peptide p lasma concentrat ions in dialy­sis-dependent chronic renal fai lure and in patients wi th elevated left ventr icular f i l l ing pressure 430

Hauschi ld A -» Mönig Η Hausser S -> Haak Τ Häussinger D -» Hafkemeyer Ρ Hay ID -> Heufelder AE Hebert SC, Gamba G: Molecular c loning

and character izat ion of the renal diuret­ic-sensit ive electroneutral sodium-(po-tassium)-chlor ide cotransporters 692

Hecker Η -> Ranke C Heil ig Β Arnold JC Heimpel Η -» L immer J Helber U Spyr idopoulos I

VI

Held I -> Einhaus Μ He lmchen U -» A lbrecht Η Helm EB Kamps BS Hemmer l i ng AE -» Wagner D Hengge U -> Malessa R Her ing W Tschaikowsky Κ Hermann J - • Wascher TC Her rW, Schwer t ing A, Wit t ig B, Wani-

tschke R, S c h n i t z l e r G , W e i n e r t h J , Jo-chum W, Hake U, Meyer zum Büschen­fe lde K-Η: Enormous hemang iosa rcoma of the hear t 372

Heufe lder AE, Hay ID: Ev idence for au ­t o immune mechan isms in the evo lu t ion of invasive f ib rous thyro id i t is (Riedel 's s t ruma) 788

H e y d e n s , Kluthe R, I m m e n h o f e r C : Inter­nat ional Sympos ium on Sod ium and Hy­per tens ion. Results of randomized t r i ­als 800

Hi lber t Ν -> Hol lenbeck Μ Hirschl M M , Gwechenberger Μ, Zehe tg ru -

ber Μ, Weber Η: Severe compl i ca t ions fo l lowing th romboly t ic therapy of an acute th rombos is of a prosthet ic mi t ra l va lve 466

H o e k s t r a J H : Acute gast roenter i t is in Eu­rope and the use of ora l rehydra t ion therapy 167

Hoffmann G -> Düsing R Hof fmann GE Br iege l J Hof fmann Κ -+ Adamek RJ Hoffmeister HM -> Spyr idopou los I Hofmann D Engelste in Ε Hohagen F - * Bauer J Höhler T, Teuber G, Wani tschke R, Meyer

zum Büschenfe lde K-Η: Indomethac in t reatment in amphote r i c in Β induced nephrogen ic d iabetes ins ip idus 769

Holhorst Κ - * K l iem V Hol lenbeck M, Hi lbert N, Meuse l F, Gra-

b e n s e e B : Increasing sensi t iv i ty and speci f ic i ty of Doppler sonograph ic de­tect ion of renal t ransp lant re ject ion wi th ser ia l invest igat ion techn ique 609

H ö l l t V -> W a n g X Holm D - * G r e m i n g e r P Holzer Η -> Ha iwachs G Holz Ο -+ Einhaus Μ Hombach V -> Haug C Hombach V -> Waidner Τ Hopferwieser Τ -> Föger Β Hoppe-Seyler F, B u t z K : Tumor suppres­

sor genes in mo lecu la r med ic ine 619 Höpp HW - Waidner Τ H o r i n a J H -> Kaufmann Ρ Hor ina JH -> Stauber RE Hor isberger J-D, Puoti A, Canessa C, Ros-

s ier BC: The ami lo r ide receptor 695 Horneff G, Dirksen U, Wahn V: ln ter feron-γ

for t reatment of severe atopic eczema in two ch i ld ren 400

Houwe l ing H: HIV t ransmiss ion in the pro­v is ion of health care 1

Huer tas-Gonzales JM -*· Perez-Bianco FJ Humphr ies S -> L indahl G Humphr ies S Schuster Η Humphr ies SE - * Seed Μ Hupper t ΡΕ - • Spyr idopou los I

I m m e n h o f e r C -> Heyden S

Inscho EW -+ Navar LG Irsigler Κ -> Pecherstorfer Μ Iser G, Pfohl M, Dörr U, Weiss EM, Seif FJ :

Ectopic ACTH secret ion due to a bron­chopulmonary carc ino id local ized by so­matostat in receptor sc int igraphy 887

Ishibashi Η -» Nagafuchi S Ishi iM - • Yasuda G Ittel ΤΗ - * Mertens PR Ittensohn A -> de Vries JX Ittensohn A -> Löffler W

Jablonowski H, Sander O, Wi l lers R, Adams O, Bar tmann Ρ, Wahn V: The use of intravenous immunog lobu l ins in symptomat ic HIV infect ion. Results of a randomized study 220

Jakober Β -» L ingenfelser Τ Jakob G Vorderwink ler K-P Jandik Ρ -> Mel ichar Β Janßen-Timmen U -> Haben ich tAJR Jaspers C, B e n k e r G , Reinwein D: Treat­

ment of pro lact inoma pat ients wi th the new non-ergot dopamine agonist rox in-do l : f irst results 451

Jaspersen D -> Körner Τ Jeck Τ, Weisser Β, Mengden Τ, Erd-

menger L, Grüne S, Vetter W: Pr imary a ldosteron ism: di f ference in c l in ical presentat ion and long-term fo l low-up between adenoma and bi lateral hyper­plasia of the adrenal g lands 979

Jelkmann W -> Gross AJ Jerusalem F -> Zierz S Jochum W -> Herr W Jockenhövel F, Lederbogen S, Olbr ichtT,

Schmidt-Gayk H, Krenning EP, Lam­berts SWJ, Reinwein D: The long-acting somatostat in analogue octreot ide a l lev i ­ates symptoms by reducing posttransla-t ional convers ion of prepro-g lucagon to glucagon in a patient wi th mal ignant g lucagonoma, but does not prevent tu­mor growth 127

Jodar-Gimeno Ε -> Vidal-Puig A Johnston DA, W o r m s l e y K G : Problems

with the interpretat ion of gastr ic pH measurement 12

Jos tWH, RappC, König J , S c h i m r i g k K : Are heart rate responses reproducib le in the t i l t- table test? 996

Judmaier G -> Vorderwink ler K-P Jul ius U, Fritsch H, Fritsch W, Rehak E,

Fücker K, Leonhardt W, Hanefeld M: Im­pact of hormone rep lacement therapy on postprandial l ipoproteins and l ipo­p r o t e i n ^ ) in normol ip idemic post­menopausal women 502

Jungmann Ε -* Haak Τ Jurna I, Krauß Ρ, Baldauf J : Depression by

nicotine of pain-related nocicept ive ac­tivity in the rat tha lamus and spinal cord 65

Kaboth W -> Adorf D Kahlon BMM -> Syed TA Kal l inowski Β -> Arnold JC Kamps BS, Brodt H-R, Staszewski S,

Bergmann L, H e l m E B : AIDS-free sur­vival and overal l surv ival in HIV infec­

t i on : the new CDC classi f icat ion system (1993) for HIV disease and AIDS 283

Kamradik Β Netter Ρ Karsch KR -> Strohschneider Τ Kasper-Dahm G -» Haak Τ Kassubek J Witzke Ο Kater W -> Wehrmann Τ Kat termann R -> Ensenauer R Kaufmann P, Smol le KH, H o r i n a J H , Zach

R, K r e j s G J : Impact of long-term hemo­dia lys is on nutr i t ional status in patients wi th end-stage renal fa i lure 754

Kautzky-Wil ler A Capek Μ Kawamor i T, TanakaT, Kawase Y, Shi-

roko J , Tanahashi S, Mori H: An α-feto­protein producing pancreat ic cystade-nocarc inoma 377

Kawase Υ -> Kawamor i Τ Ke l le rmann W -» Br iegel J Kel lner Η, Yu D: The pathogenesis of HLA-

B27 associated ar thr i t is : lessons f rom the B27 crystal 321

Kern Ρ -> Wagner D Kern WV Wagner D Keulers Ρ Mertens PR Khadra LF -> Benwel l MEM Kienast K, Riechelmann H, Knorst M,

Schlegel J , Mül le r -Quernheim J , Schel­lenberg J, Ferl inz R: An exper imenta l model for the exposure of human ci l iat­ed cel ls to sulfur d ioxide at dif ferent con­centrat ions 215

Kikuchi Μ -> Nagafuchi S K i m u r a T - * Mizunashi Κ K i rchhe im HR, E h m k e H : Vasoactive hor­

mones : modulators of renal funct ion 685 688

Kirchner Η -> Buer J K i rschbaum C, Scherer G, Strasburger

C J : Pitui tary and adrenal hormone re­sponses to pharmacolog ica l , physical , and psychological s t imulat ion in habitu­al smokers and nonsmokers 804

Klausen IC -> Hansen PS Klauss V -> Christ Μ Klauss V - • Rol inski Β Kleeberg S -> Haferkamp Ο Klein R, Berg PA: A comparat ive study on

ant ibodies to nucleol i and 5-hydrox-y t ryptamine in patients wi th f ib romya l ­gia syndrome and t ryptophan- induced eos inophi l ia -myalg ia syndrome 541

Kl iem V, Ringe B, Holhorst K, F r e i U : Kid­ney t ransplantat ion in hepat i t is Β sur­face ant igen car r iers 1000

K l i m p f i n g e r M Stauber RE Kl ingelhöfer J -> Sander D K l ingmül ler D -> Brennemann W Kluthe R -»· Heyden S Knappertz VA - • Kubier A Kniemeyer HW, Sandmann W, Schw ind tC ,

Grabi tz K, Torsel lo G, Stühmeier Κ: Thrombectomy wi th ar ter iovenous f istu­la for embol iz ing deep venous th rombo­s is : an al ternat ive therapy for preven­tion of recurrent pu lmonary embol ism 40

Knise lW, Pfohl Μ, Mül ler Μ, Besenthal I, d i N i c u o l o A , Voelker W, Ris lerT, Egg­stein M : Comparat ive long-term exper i ­ence wi th immunoadsorpt ion and dex-

VII

t ran sulfate cel lu lose adsorpt ion for ex­t racorporeal e l iminat ion of low-density l ipoproteins 660

Knol le Ρ -* Wölfel Τ Knorst Μ -> Kienast Κ Kobayashi I -> Kubota Κ Kobelt R -> G r e m i n g e r P Koch KM -+ Brunkhorst R Kochs Μ -> Haug C Köhler Η -> Adamek RJ K o h l e r S M -> Krämer BK Koizumi Τ -> Takeda Μ Komeyama Τ Takeda Μ Komlosi Ρ - • Nagy I Kommere l l Β -> Arno ld JC Kommere l l Β -> Boehme MWJ Kommere l l Β - * Sch lenke rT König J -> Jost WH König W -» Fischer A Konz Κ -> Luft D Koray Ζ -> Bayraktar Μ Körner Τ, Kropf J , Jaspersen D, Hammar

C-H, G r e s s n e r A M : On the diagnost ic potential of f ibronect in in human bi le f lu­id 316

Korte W, F e l d g e s A : Increased pro throm­bin act ivat ion in a patient with congeni ­tal a f ib r inogenemia is revers ib le by f ibr inogen subst i tut ion 396

Kört ing HC -> Schäfer-Kört ing Μ Κο Υ -> Schmitz U Κο YD -» Flesch Μ Kraft Κ Flesch Μ Krämer BK, Ackermann Μ, K o h l e r S M ,

Riegger G A J : Role of endothel in in hy­pertension 88

Krämer G -> Kubier A Kramer HJ - * Bokemeyer D Kramer HJ, Bäcker A, Bokemeyer D,

Meyer-Lehner t Η: Atr ia l natr iuret ic pep­t ide and endothe l in : modulators of renal function 703

Kramer HJ: Mul t ip le scienti f ic publ ica­t ions 555

Krams Μ -> Malessa R Krause Τ -> Einhaus Μ Krauß Ρ -> Jurna I Krejs GJ -> Wascher TC Krejs GJ -> Kaufmann Ρ Krejs GJ - * Stauber RE Krenning EP -» Jockenhövel F Kr ieger S -» Bauer J Kropf J -> Körner Τ Krüger TM -> Stempfle HU Kubier A, Rothacher G, Knappertz VA,

Krämer G, Nink M, Beyer J, L e h n e r t H : Intra- and ext racerebra l b lood f low changes and f lushing after int ravenous inject ion of human cor t icot ropin-re leas-ing hormone 331

Kubier W Ni roomand F Kubota K, T a m u r a J , Kurabayashi H, Shi -

rakura T, Kobayashi I: Evaluat ion of in­creased se rum ferr i t in levels in patients with hyper thyro id ism 26

Kuntz C -> Wolf Ο Kurabayashi Η -+ Kubota Κ Kutzer C -> Falter Β

Lamberts SWJ -> Jockenhövel F Landthaler Μ - * Wagner DR

Landthaler R -> de Vries JX Landthaler R -> Loftier W L a n d W : Impact of the reperfusion injury

on acute and chronic reject ion events fo l lowing cl in ical cadaver ic renal trans­plantat ion 719

Lange S -> Mönig Η Lanzer Η -» Haiwachs G Lardel l i Ρ Vidal-Puig A Laso FJ, Cordero M, Garcia-Sänchez JE:

Esophageal bruce l los is : a new location of Brucel la infection 393

Laso FJ, Madruga I, Borräs R, Bajo A, Gonzalez-Bui t rago JM, Castro de S: Hy­pokalemia in opiate overdose 471

La Spada AR Danek A Lassau Μ Hagendorff A Läszlo Jr F - * Nagy I LDL Apheres is Study Group -+ Wa idnerT Lebeau A - * Rob PM Lechlei tner Μ Föger Β Lederbogen S -> Jockenhövel F Lehnert Η - * Kubier A Lehner tT -> Wolf Ο Le ibhammer S -> Düsing R Leipner Ν Brennemann W Leonhardt W -»· Jul ius U Lewalter J -> Evers J Liegl U, Bogner JR, Goebel FD: Insulin-de­

pendent diabetes mel l i tus fol lowing pentamidine therapy in a patient with AIDS 1027

L immer J , El lbrück D, Mül ler Η, Eisele Ε, R i s t J , Schütze F, Beger Η, Heim-pel H, Seifr ied Ε: Prospect ive random­ized cl in ical study in general sur­gery compar ing a new low molecular weight hepar in wi th unfract ionated hep­ar in in the prevent ion of thrombosis 913

Lindahl G, Mai l ly F, Humphr ies S, Seed M: Apol ipoprote in Ε phenotype and l ipo­p r o t e i n ^ ) in fami l ia l hypercholestero­l e m i a : impl icat ion for l ipoprotein(a) metabol ism 631

L ine tO i , N e f f L L ' Intracavernous prosta­glandin Έ.Λ in erect i le dysfunct ion 139

Lingenfelser T, Pickert A, Pfohl M, Renn W, R a d j a i p o u r M , Col let C, Eggstein M, J a k o b e r B : Hypothalamic-pi tu i tary act i­vat ion does not differ dur ing human and porcine insul in- induced hypoglycemia in insul in-dependent diabetes mell i tus 56

Lippoldt A - * Fuxe Κ Lis S -» Bauer J Loftier Η -> Harten Ρ Loftier W -> de Vries JX Löffler W, Landthaler R, de Vries JX, Wal­

ter-Sack I, I t tensohn A, Voss Α, Zöl lner Ν: Interact ion of a l lopur inol and hy­drochloroth iaz ide dur ing prolonged oral administ rat ion of both drugs in normal subjects. I. Uric acid kinetics 1071

Lohrmann Ε -> Greger R Lopez-Hänninen Ε -> B u e r J Lorenz J , Fr iedberg Τ, Paulus R, Oesch F,

Ferl inz R: Oncogene overexpression in non-smal l -cel l lung cancer t issue: prevalence and c l in icopathological s ig­nif icance 156

Lüder i tz Β - * Hagendorf f A Ludvik Β -+ Capek Μ Ludwig Μ -> Schmi tz U Luft D, Pagal l ies OB, Konz K, Mann K,

Renn W, Eggstein Μ : Dif ferent ial d iag ­nosis of neuropath ic les ions in d iabet ic and a lcohol ic pat ients 200

Lundin S Syed TA Luska G -> Ranke C

Madruga I -+ Laso FJ Magnan i G -» Pedrett i G Mai l l y F -> L indahl G Mai l ly F Seed Μ Maio A Yasuda G M a i r J -> Vorderw ink le r K-P Ma lessa R, Diener H-C, O lb r ich tT , Böh­

mer B, B rockmeyer N H : Successful t rea tment of men ingoencepha l i t i s cau­sed by Mycobac te r ium av ium in t race l lu ­l a r in AIDS 850

Ma lessa R, K rams Μ, Hengge U, Wei i ler C, Reinhardt V, Volbracht L, Rauhu tF , B rockmeyer N H : Elevat ion of in t racra­nial p ressure in acute AIDS-re lated cryptococcal men ing i t i s 1020

Mal i r F - • Me l i char Β Ma l lmann R -»· Bye S Mann Κ -> Danek A Mann Κ -+ Luft D Manns Μ -> Buer J Mar l i nghaus EH - * Wehrmann Τ Mar t inez Matos JA -» Gomez Säez JM Mar t inez Ε -> Col lazos J März W -> Haak Τ Maurer I, Z ierz S: Mi tochondr ia l resp i ra to­

ry cha in enzyme act iv i t ies in te t ra logy of Fallot 358

Mayo J -»· Co l lazos J Meh D -> Denis l ic Μ Meiner tz Η Hansen PS Meißner R -> Einhaus Μ Mel ichar Β, Jandik Ρ, Tichy Μ, Mal i r F,

M e r g a n c o v a J , V o b o r i l Z : Ur inary zinc excret ion and acute phase response in cancer pat ients 1012

Mengden Τ Jeck Τ Mens ing Η A lbrecht Η M e r g a n c o v a J -> Me l i char Β Mer tens PR, Duque-Reina D, Ittel ΤΗ, Keu­

lers Ρ, S i e b e r t h H - G : Cont rast -enhan­ced computed tomography for d e m o n ­strat ion of b i la tera l renal cor t ica l necro­sis 499

Metze le A -> Haug C Meuse l F Hol lenbeck Μ Meyer -Lehner t Η - * Bokemeyer D Meyer -Lehner t Η - * K ramer HJ Meyer zum Büschenfe lde K-Η - * Herr W Meyer zum Büschenfe lde K-Η -> Höhler Τ Meyer zum Büschenfe lde KH Wölfel Τ Middeke Μ -> Wagner DR M i e r s c h W - D -> Gross AJ Miesenböck G -> Föger Β Mizunash i Κ, Sh ish idoT, FurukawaY, En­

do K, Ota K, K i m u r a T , A b e K : Erythro-cytosis in pseudohypopara thy ro id i sm type I 341

Mizunash i K, Takaya K, Sato Η, Mor i S, Abe Κ, Furukawa Υ: The t ime course of renal funct ion and bone tu rnover in

VIII

parathyroid cr isis du,me to intratumoral hemorrhage 448

M izusawaT -> Takeda Μ Möl ler Μ -> Baldus Μ Mönig Η, Hauschi ld Α, Lange S, Fölsch

\JR: Suppressed thyroid-st imulat ing hormone secret ion in patients treated with inter leukin-2 and in te r fe ron-a 2 b for metastatic melanoma 975

Monticel l i A -> De Lorenzo F Moreno-Terr ibas G -> Perez-Bianco FJ Mori Η -> Kawamor i Τ Mori S -> Mizunashi Κ Morukov BV -> G r i go r i evA l Mrowka C, Sieberth HG: Circulat ing adhe­

sion molecules ICAM-1, VCAM-1 and E-select in in systemic vascul i t is : marked dif ferences between Wegener 's g ranu­lomatosis and systemic lupus erythe­matosus 762

MuleyT, Wiebel M, Schulz V, Ebe r tW: Elastinolyt ic activity of a lveolar macro­phages in smoking-associated pulmo­nary emphysema 269

Müller-Felber W -> B e h r T Mül ler Η -> L immer J Müller Μ -> Knisei W Müller MJ -> Netter Ρ Müller MJ, Böker KHW, Seiberg Ο: Meta­

bol ism of energy-y ie ld ing substrates in patients with l iver c i r rhosis 568

Mül ler -Quernheim J -> Kienast Κ Mundegar RR -> Z i e r z S Munoz-Torres Μ - * Vidal-Puig A Murer Η, B r e c h W : Editor ial 681 Müsch Ε -> Witzke Ο

Nagafuchi S, Ishibashi H, Anzai K, Ohshi-ma K, Ohno Y, Fukushima N, Hashi-zume M, Sugimachi K, Chuman H, Ki-kuchi M, N ihoY Budd-Chiar i syndrome and Epstein-Barr v i rus (EBV) associated p lasmacytoma in a patient with chronic active EBV infection 883

Nagy I, Pogatsa-Murray G, Z a l a n y i J r S , Komlosi P, L a s z l o J r F , U n g i l : Amani ta poisoning dur ing the second t r imester of pregnancy. A case report and a review of the l i terature 794

N a k a m a H : A study on the efficacy of a screening program for colorectal cancer in a smal l Japanese v i l lage 117

Navar LG. Inscho EW, Harr ison-Bernard LM, TakenakaT: Paracr ine interact ions regulat ing renal microci rculatory func­tion 682

Navarro MA - * Gomez JM Navarro Moreno MA Gomez Säez JM Neff LL L ine tOI Neri C Adorf D Netter P, Mül ler MJ, Neumann A, Kam-

r a d i k B : The inf luence of nicotine on performance, mood, and physiological parameters as related to smoking habit, gender, and suggest ibi l i ty 512

Neumann A -> Netter Ρ Neumann Η.P.Η.: Genetics of hyperten­

s ion : the pheochromocytoma model 729

Neupe r tW: Transport of proteins across mitochondr ia l membranes 251

Neurath G B : Aspects of the oxidat ive me­tabo l ism of nicotine 190

di Nicuolo A -> Knisei W N i h o Y -» Nagafuchi S Ni in ivaara-Kreuzer Κ -> Wintergerst U Nink Μ -+ Kubier A N i roomand F, Kubier W: Hibernat ing, stun­

ning and ischemic precondi t ioning of the myoca rd ium: therapeut ic impl ica­t ions 731

Notheis G -> Wintergerst U

Obara Κ -> Takeda Μ Oberhoff Μ -> Strohschneider Τ Oesch F -> Lorenz J Offensperger W-B, B lum HE, Gerok W:

Molecu lar therapeut ic strategies in hep­atit is Β v i rus infection 737

Ohno Y -> Nagafuchi S Ohsh ima Κ -> Nagafuchi S O lb r i ch tT -> Jockenhövel F O lb r i ch tT -> Malessa R O lb r i ch tT -> Rzepka AH Olek Κ - • Schröder R Omran Η -> Hagendorff A Ortolä J -> Gomez JM Ostrowi tzk i S, Z i e r z S : Two cases of neu­

ro logical manifestat ions in eos inoph i l ia : var ia t ions of one d isease? 1060

Ota Κ -> Mizunashi Κ Otto G -> Arno ld JC Otto G -+ Feussner G

Pagal l ies OB -> Luft D Patscheider S -> Vogetseder W Patsch JR -> Föger Β Paulus R -> Lorenz J Pecherstor fer Μ, Z immer-Roth I, Weidin­

ger S, Irsigler Κ, Halbmayer WM, Ul­r ich W, Fischer M, Baumgar tner G: High-dose intravenous melphalan in a patient wi th mult ip le myeloma and o l ig­uric renal fa i lure 522

Pedrett i G, E l i a G , Calzett i C, Magnani G, Fiaccador i F: Octreot ide versus terly-pressin in acute var iceal hemorrhage in l iver c i r rhos is . Emergency control and prevent ion of ear ly rebleeding 653

Perez-Bianco FJ, Huertas-Gonzales JM, Moreno-Terr ibas G, Rodr iguez-Cuartero A : Ur inary excret ion of N-acetyl-ß-glu-cosamin idase in sl ight arter ia l hyper­tension dur ing pregnancy 799

Peter Κ -> Br iegel J Peters J Wehrmann Τ Pfei lschif ter J : Cytokines and signal t rans­

duct ion 713 Pfohl Μ Iser G Pfohl Μ Knisei W Pfohl Μ -> Lingenfelser Τ Phi l ippe J -> Pinet F Phosphol ipase A 2 Study Group Br ie-

gei J P i cke r tA -» Lingenfelser Τ Pietschmann Ρ - * Er lacher L Pi lger Ε -> Decrinis Μ Pinet F, Germain S, Borensztein P, Fuchs

S, Phi l ippe J, Corvol P: Molecular mech­an isms in renin control 688

Pizzul l i L -> Hagendorff A Pl iml W -> Christ Μ

Pogätsa-Murray G Nagy I Pol iwoda Η -> Buer J Ponce-Pöschl Ε - * Schäfer-Kört ing Μ Pongratz D -»> Behr Τ Poser W -»· Ehrenreich Η Postler Ε -> Bauer J Prager R -> Capek Μ Presterl Ε Sexl V Puoti A -> Hor isberger J-D Puschendorf Β -> Vorderwink ler K-P Püttmann Μ -> Ensenauer R

Queißer W Baldus Μ Quintel Μ -* Ensenauer R

Radjaipour Μ Lingenfelser Τ Raedsch R -» Sch lenke rT Raeth U - Boehme MWJ Rainer F - * Wascher TC Ramador i G -+ Schwörer Η Ranke C, Creutzig A, Luska G, Wagner H-

H, Galanski M, Bode-Böger S, Fröl ich J , Avenar ius H-J, Hecker H, A lexander Κ: Control led tr ial of h igh-versus low-dose aspir in t reatment after percutaneous t rans luminal angioplasty in pat ients wi th per ipheral vascular disease 673

Rapp C -+ Jost WH Ratschek Μ -> Stauber RE Rauhut F Malessa R Rehak Ε - * Jul ius U Reichel C, Fehske W, Fischer HP, Hart-

l a p p J H : Undif ferentiated (embryonal) sarcoma of the l iver in an adult patient with metastasis of the heart and brain 209

Reinhardt V Malessa R Reinwein D -> Jaspers C Reinwein D -> Jockenhövel F Reinwein D ~> Rzepka AH Reinwein D -> Wagner R Reisinger EC Haiwachs G Reiterer L -> Schneider Τ Renn W Lingenfelser Τ Renn W - • Luft D Renner Ε -> Evers J Richter Ε -> Falter Β Riechelmann Η Kienast Κ Riecken EO -+ Schneider Τ Riegger GAJ -> Krämer BK Ringe Β -> Kl iem V R i s l e rT Knisei W Risti B, Flury RF, Schaffner A : Fatal hema-

tophagic hist iocytosis after granulocyte-macrophage colony-st imulat ing factor and chemotherapy for h igh-grade mal ig ­nant lymphoma 457

R is t J L immer J Ritsch A -> Föger Β Ritter Μ -> Waidner Τ Ritz Ε - * Fliser D Rob PM, Goebel Y, Lebeau A, Classen H-

G: Myocardia l magnes ium deplet ion dur ing cyc lospor ine t reatment, associat­ed with reciprocal ca lc ium over load, can be prevented by plent i ful d ietary magnes ium supply 137

Rödel G -» Haferkamp Ο Rodr iguez-Cuartero A -> Perez-Bianco FJ Rolinski B, Geier SA, Sadri I, Klauss V,

Bogner JR, Ehrenreich H, Goebel FD:

IX

Endothel in-1 immunoreact iv i ty in plas­ma is elevated in HIV-1 infected patients wi th ret inal microangiopathic syn­d rome 288

Romalo G -> Danek A Roots I -> Drakoul is Ν Rose BD: Resistance to diuret ics 722 Rosen L Fuxe Κ Rossier BC -> Horisberger J-D Rothacher G -> Kubier A Rothe EM - * Sch lenkerT Rubba Ρ -> De Lorenzo F Rüdiger HW -»· Einhaus Μ Rügheimer Ε -> Tschaikowsky Κ Ruiz-Requena ME -> Vidal-Puig A R z e p k a A H , Cissewski K, Ulbr icht T, Rein­

we in D: Effectiveness of prophylact ic therapy on goiter recurrence in an area wi th low iodine intake - a sonographic fo l low-up study 967

Saal JG -> Spyridopoulos I Sabin Κ -> Haiwachs G Sabol ic I, Brown D: Water t ransport in re­

nal tubules is mediated by aquapor ins 698

Sachin id is A -> Flesch Μ Sadri I Rolinski Β Sagarra Ε -> Fernandez-Real JM Sahota A -> Bye S Salv ioni G - * Antonell i A Sander D, Scholz CW, Eiben P, K l ingel -

höfer J : Postvaccinal plexus neuropathy fo l lowing vaccination against t ick-borne encephal i t is and tetanus in a compet i ­t ive athlete 399

Sander Ο -> Jablonowski Η Sandmann W -» Kniemeyer HW Sato Η -+ Mizunashi Κ Schaefer Η -> Feussner G Schäfer-Kört ing Μ, Kört ing HC, Ponce-

P ö s c h l E : Liposomal t ret inoin for un­compl icated acne vulgar is 1086

Schaffner A -> Risti Β Schel ienberg J -> Kienast Κ Scherer G -* Chajek-Shaul Τ Scherer G Einhaus Μ Scherer G -> K i r s c h b a u m e Scherübl Η -> Schneider Τ Schett ler G -» HabenichtAJR Schewe CK, Schweikart HP, Hammel G,

Spengel FA, Zöl lner N, Zol ler W G : Influ­ence of selective management on the prognosis and the risk of rupture of ab­domina l aortic aneurysms 585

Schimr igk Κ -» Jost WH Schi rmacher Ρ -> Wölfel Τ Schlaak J -+ Wölfel Τ Schlegel J -> Kienast Κ Sch lenkerT, Raedsch R, DeVries JX,

Schmi tz-Kummer E, Walter-Sack I, Ro­the EM, Kommerei l Β: Sel f -medicat ion for abdominal discomfort result ing in l i fe-threatening consequences 74

Schmidt-Achert Μ -> B e h r T Schmidt-Gayk Η -> Jockenhövel F Schmitt-Gräff A -> Schneider Τ Schmi tz-Kummer Ε -> Sch lenkerT Schmitz U, Κο Υ, Becher Η, Ludwig Μ, Vet­

ter Η, Düsing R: Evidence for card iovas­

cular remodel ing in a patient with Bax ­ter 's syndrome 874

Schmitz U, Κο Y, Seewald S, Düsing R, Vet­ter Η: Iron-def ic iency anemia as the sole manifestat ion of cel iac disease 519

Schnabel A -> Dih lmann W Schnack C - * Capek Μ Schneider Τ, Ul l r ich R, Scherübi H,

Schmitt-Gräff A, Stein H, Riecken EO, Zeitz Μ : Intestinal intraepi thel ia l Τ cel l der ived lymphoma not associated wi th enteropathy 313

Schneider T, Ul l r ich R, Schmitt-Gräff A, Bergs C, Rei terer L, Dissmann T, Zeitz Μ, Riecken EO: Baci l lary angiomatosis in a German patient wi th AIDS 50

Schnitz ler G Herr W Schol lmeyer PJ Dobos GJ Scholz CW Sander D Schomburg A -> Buer J Schröder R Behrens S Schröder R, B e y e n b u r g s , Weber J, Olek

K, Z ierz S: Myotonic dystrophy and l imb g i rd le muscular dystrophy in one fami ­ly 409

Schröder R, Urbach H, Z ierz S: Cauda equina syndrome with mult ip le lumbar d iver t icula compl icat ing long-standing ankylosing spondyl i t is 1056

Schüler A -»· Buer J Schulz V -> Muley Τ Schupp Μ -> Hafkemeyer Ρ Schuster Η, Humphr ies S: European Work­

ing Group on Famil ial Hypercholesterola em ia : European Workshop on LDL Re­ceptor Defects 898

Schuster HP - * Bodmann KF Schütze F -» L immer J Schuurman H-J: Molecular mechanisms of

t ransplant reject ion 715 Schwart ing A Herr W Schweikar t HP Schewe CK Schweiker t HU -> Danek A Schw ind tC -> Kn iemeyer HW Schwörer H, R a m a d o r i G : Treatment of

acute gouty arthr i t is wi th the 5-hydroxy-t ryptamine antagonist ondansetron 811

Seed Μ - • Lindahl G Seed Μ, Ma i l l yF , Val lance D, Doherty E,

Winder A, Talmud P, Humphr ies SE: L i ­poprotein l ipase activity in patients wi th combined hyper l ip idaemia 100

Seewald S -> Schmitz U Seibold Η -> Haferkamp Ο Seidel D Windler Ε Seif FJ Iser G Seifr ied Ε -> L immer J Seiberg Ο - * Mül ler MJ Sesto Μ -*• Solaj ic-Bozicevic Ν Sexl V, Wagner L, Wiesholzer M, Presterl

E, B a s e W : Treatment of a patient wi th mal ignant mesothe l ioma with interfer-on -a 2 based on in vi tro sensit iv i ty tests 317

Shi loni Ε -> Chajek-Shaul Τ Shionir i Η -> Yasuda G Shirakura Τ - * Kubota Κ Sh i r okoJ -> Kawamor i Τ Sh ish idoT -> Mizunashi Κ Sieberth H-G Mertens PR

Sieber th HG - * Mrowka C S iekmeier R -»· Haak Τ Siffert W -> Düsing R S immonds HA -> Bye S Sittl R - • Tschaikowsky Κ Smol le KH Kaufmann Ρ Soergel K H : Colonic fe rmen ta t i on : meta­

bol ic and c l in ica l impl icat ions 742 Sola j ic -Bozicev ic N, Stav l jen ic-Rukavina

A, Sesto Μ : Leci th in-cholestero l acy l -t ransferase act iv i ty in pat ients wi th co ronary ar tery d isease examined by coronary ang iography 951

S o l e r J -> Fernändez-Real JM Soler J Gomez JM Spengel FA -> Schewe CK Spyr idopou los I, Helber U, Voelker W, Hup­

pert ΡΕ, Gär tner HV, Saal JG, Hoffmeis­ter H M : Pr imary systemic amylo idos is lead ing to advanced renal and card iac invo lvement in a 30-year old man 462

Stachan-Kunstyr R -> Wagner D Stahl RAK, Wolf G, Thaiss F: The possib le

ro le of chemotact ic cytok ines in renal d isease 711

Stark G -»• Decr in is Μ Staszewski S Kamps BS Stauber RE, H o r i n a J H , Trauner Μ, Kre js

GJ, Ratschek M, K l impf inger Μ : Glo­meru lonephr i t i s as late mani festat ion of severe o^-ant i t rypsin def ic iency 404

Stauch Μ -> Haferkamp Ο Stav l jen ic-Rukav ina A -»· Sola j ic -Boz ice­

vic Ν Stech C -> Feussner G Steffgen J -> Haug C Stein Η Schneider Τ Stein Ο - * Chajek-Shaul Τ Stein Y - • Chajek-Shaul Τ Stel lbr ink HJ -> A lbrecht Η Stel lbr ink HJ, A lbrecht H, Greten H: Pneu­

mococca l parot i t is and cerv ica l lymph node abscesses in an HIV-infected pa­t ient 1037

Stempf le HU, Krüger T M , Brandl BC, The i -sen Κ, A n g e r m a n n CE: S imul taneous t ransesophagea l echocard iography and atr ia l pac ing : assessment of the func­t ional s ign i f icance of coronary ar tery d isease before surg ica l t reatment of an abdomina l aneurysm 206

Storch Μ -+ Hafkemeyer Ρ St rasburger CJ ->· K i r s c h b a u m e St rohschne ider Τ, Oberhoff Μ, Hanke Η,

Hannekum A, Karsch KR: Effect of chron ic n icot ine de l ivery on the pro­l i ferat ion rate of endothe l ia l and smooth musc le cel ls in exper imen ta l ­ly induced vascu lar wal l p laques 908

Stühmeier Κ -> Kn iemeyer HW Sugimachi Κ -> Nagafuchi S Suter PM -> G r e m i n g e r P Syed TA, L u n d i n S , Cheema KM, Kah-

lon B M M , Cheema R, Ahmad SA, Ah ­mad Μ : Human leukocyte in ter feron-α in c ream, for the t rea tment of geni ta l war ts in as ian w o m e n : a p lacebo-cont ro l led, doub le-b l ind study 870

Sz iego le i tA -> Füssle R

χ

Takahashi Η Takeda Μ Takaya Κ -> Mizunashi Κ Takeda Μ, Hatano A, Takahashi Η, Tama-

ki M, Komeyama T, Koizumi T, Tsutsui T: ^ -Ad renocep to r s in the human prostat­ic urethra are different f rom those of the human per ipheral ar ter ies 55

Takeda Μ, Komeyama Τ, Koizumi Τ, Hata­no A, Tamaki M, Takahashi H, Tsutsui T, Mizusawa T, Obara K: Endothel in recep­tors in the human ur inary bladder are different f rom those in the human ureter 213

Takenaka Τ -> Navar LG Talmud Ρ -> Seed Μ Tamaki Μ - * Takeda Μ Tamura J -+ Kubota Κ Tanahashi S -» Kawamor i Τ Tanaka Τ -> Kawamor i Τ Tegtmeyer KF -> Wetterl ing Τ Telenti A : Molecular diagnost ics for infec­

t ious d iseases: where do we stand? 415

Terres W -> Engelstein Ε Teuber G -+ Höhler Τ Teufelsbauer Η Erlacher L Thaiss F -> Stahl RAK Thei lmann L -> Arnold JC Theisen Κ -> Christ Μ Theisen Κ - * Stempfle HU Thiery J -> Windler Ε Thoma HA -> Wagner D Tichy Μ -» Mel ichar Β T immer J -> Bauer J Tiran A - * Haiwachs G Tischfield JA -> Bye S Torse l loG -> Kniemeyer HW Trauner Μ -> Stauber RE Traynor-Kaplan AE -> Dobos GJ Tr ickerAR -* Einhaus Μ Tröbinger G -»· Föger Β Tröster S -» Bodmann KF Tschaikowsky K, Sittl R, Braun GG, Her­

ing W, R ü g h e i m e r E : Increased fMet-Leu-Phe receptor expression and a l ­tered superoxide product ion of neu­trophi l granulocytes in septic and post­t raumat ic patients 18

Tsutsui Τ Takeda Μ

Uhl W Br iegel J Ul lr ich R Schneider Τ Ulr ich W -> Pecherstorfer Μ Umemura S -» Yasuda G Ungi I -> Nagy I Urbach Η - • Schröder R Usadel K-H - Haak Τ Usman A - * Bayraktar Μ

Vallance D -> Seed Μ Vetrie D -> Fl inter F Vetter Η -> Düsing R Vetter Η -» Flesch Μ Vetter Η -> Schmitz U Vetter W -> Greminger Ρ Vetter W -> Jeck Τ Vidal-Puig A, Muhoz-Torres M, Jodar-Gi-

meno E, Garcia-Calvente C, Lardel l i P, Ruiz-Requena ME, Escobar-J imenez F: Hyper insul inemia in polycystic ovary

Syndrome: relationship to c l in ical and hormonal factors 853

Vi l labona C - * Fernändez-Real JM Vobori l Ζ -> Mel ichar Β Voderholzer U -> Bauer J Voe lke rW - Knisei W Voe lke rW -> Spyr idopoulos I Voe lke rW -> Wa idne rT VogetsederW, Fil le M, Patscheider S, Die-

r ich MP, A l le rberger F: Molecular ep i ­demio logy of tuberculos is in Aust r ia 107

Volbracht L Malessa R Vorderwink ler K-P, Jakob G, M a i r J , Jud -

m a i e r G , Puschendorf B: Uncoupl ing of atr ial natr iuret ic pept ide and cycl ic guanosine 3 ' ,5 ' -monophosphate produc­t ion in patients wi th l iver c i r rhos is 138

Vorobiev DV Gr igor iev AI Voss A -> de Vries JX Voss A - • Löffler W de Vries JX -+ Löffler W de Vries JX, Voss A, Ittensohn A, Walter-

Sack I, Löffler W, Landthaler R, Zö l lner Ν: Interaction of a l lopur inol and hy­drochloroth iaz ide dur ing pro longed oral administ rat ion of both drugs in normal subjects. II. Kinet ics of a l lopur ino l , ox-ipur inol , and hydrochloroth iaz ide 1076

Wagenbreth I - * Wagner D Wagner D, Kern WV, Kern Ρ: L iposomal

doxorubic in in AIDS-related Kapos i 's sa rcoma: long-term exper iences 417

Wagner D, Wagenbreth I, Stachan-Kun-styr R, Thoma HA, Hemmer l ing AE, Flik J : Hepatit is Β vaccinat ion of im-munosuppressed heart t ransplant rec ip­ients with the vaccine Hepa Gene 3 con­taining pre-S1, pre-S2, and S gene p rod­ucts 350

Wagner DR, Eckert F, Gresser U, Land­thaler M, Middeke M, Zöl lner Ν: De­posits of paraprote in in smal l vessels as a cause of skin ulcers in Waldenst rom's macrog lobu l inemia 46

Wagner H-H -» Ranke C Wagner L -> Sexl V Wagner R, Bonifacio E, Bingley PJ, Gen-

ovese S, Reinwein D, Bottazzo GF: Low inter leukin-2 receptor levels in se rum of patients wi th insul in-dependent d ia­betes 494

Wagner TOF Flüge Τ Wahn V -» Horneff G Wahn V Jablonowski Η WaidnerT, Franzen D, VoelkerW, Ritter Μ,

Borberg Η, Hombach V, Höpp HW, LDL Apheresis Study Group : The effect of LDL apheresis on progression of co ro ­nary artery d isease in patients wi th fa­mi l ia l hypercholestero lemia. Results of a mult icenter LDL apheresis study 858

Walewska-Zielecka Β Habior A Wall! A Windler Ε Walter Η Baldus Μ Walter-Sack I de Vries JX Walter-Sack I -> Löffler W Walter-Sack I -> Sch lenke rT Wang X, Bacher B, H ö l l t V : Nicot ine- in­

duced gene expression of proenkephal -in in bovine chromaff in cel ls 925

Wanitschke R -> Herr W Wanitschke R -»• Höhler Τ Wanner C -» Bartens W Ward D - * Dobos GJ Warncke Κ Einhaus Μ Wascher TC, Hermann J, Brezinschek HP,

Brezinschek R, Wi lders-Truschnig M, Rainer F, Krejs GJ : Cel l- type specif ic re­sponse of per ipheral blood lymphocytes to methotrexate in the t reatment of rheumatoid arthr i t is 535

Weber Η -> Hirschl MM Weber J - • Schröder R Wegener Μ -*• Adamek RJ Wehling Μ Christ Μ Wehrmann Τ, Kater W, Mar l inghaus EH,

Peters J , C a s p a r y W F : Shock wave t reatment of sal ivary duct s tones: sub­stantial progress with a mini l i thotr ipter 604

Weidinger S -> Pecherstorfer Μ Weil ler C -> Malessa R Weinerth J -» H e r r W Weissel Μ -»· Er lacher L Weiss EM Iser G Weisser Β Jeck Τ Wenisch C, Etzersdorfer E, Breyer S, Gra-

n i n g e r W : Intravenous te icoplanin does not prevent Clostr id ium diff ici le associ ­ated d iar rhea 922

Werle Ε -> Boehme MWJ Wetterl ing T, Tegtmeyer KF: Serum (^-an­

t i t rypsin and ot 2 -macroglobul in in Alz­he imer 's and B inswanger 's d isease 196

Wetter S -> Hagendorff A Wiebel Μ -> Muley Τ Wienbeck Μ -> Adamek RJ Wiesholzer Μ -> Sexl V Wilders-Truschnig Μ -» Haiwachs G Wilders-Truschnig Μ -» Wascher TC Wil lers R -> Jablonowski Η Winder A Seed Μ Windler Ε, Ewers-Grabow U, Thiery J , Wal-

Ii A, Seidel D, Greten H: The prognost ic value of hypocholestero lemia in hospi ­tal ized patients 939

Wintergerst U, Ni in ivaara-Kreuzer Κ, Not-heis G, Auberger K, Brückmann C, Gan-denberger S, Belohradsky BH: High­dose intravenous immunoglobu l ins in the t reatment of adolescent and adult HIV-infected hemophi l iacs 122

Witt ig Β -+ Herr W Witt TN -> Danek A Witzke Ο, Kassubek J , Bonmann E, Müsch

E: Cryog lobu l inemia : a compl icat ion of infectious disease 1048

Wizemann V: Hemodia lys is : 70 years 720 Wolf Ε -» Harten Ρ Wölfel Τ, Schi rmacher Ρ, Schiaak J , Knol le

Ρ, Dienes HP, Dippold W, Meyer zum Büschenfelde KH, Gerken G: Sustained el iminat ion of hepatit is Β virus f rom serum induced in a patient with chron ic hepatit is Β and advanced human im­munodef ic iency v i rus infection 1030

Wolff Μ Gross AJ Wolf G -> Stahl RAK

XI

Wolf Ο, Glaser F, Kuntz C, Lehne r tT : En­dorectal u l t rasound and le iomyosarco­ma of the rectum 381

Wormsley KG -> Johnston DA Wrenger Ε - * Brunkhorst R

Yasuda G, Z ierer R, Maio A, Shionir i H, Ish i iM, Umemura S Ammon ium urate nephro l i th ias is in a var iant of Bart ter 's syndrome with intact renal tubular func­t ion 385

Yu D -> Kel lner Η

Zach R -> Haiwachs G Zach R Kaufmann Ρ

Zalänyi Jr S -> Nagy I Zehetgruber Μ -» Hirschl MM Zei tz Μ -> Schneider Τ Z ieg ler R -> Feussner G Zieg ler R -+ HabenichtAJR Z ierer R - * Yasuda G Z ierz S -> Maurer I Z ie rz S Ostrowitzki S Z ie rz S Schröder R Z ierz S, Mundegar RR, Jerusalem F: Bio­

chemical evidence for heterozygosity in muscular carni t ine palmitoyl t ransferase deficiency 77

Z i e r z S : Limited t rypsin proteolysis ren­ders carni t ine palmitoyl t ransferase in­

sensit ive to inhibi t ion by malonyl-CoA in patients with muscle carni t ine pa lmi toy l ­t ransferase def ic iency 957

Z immer-Roth I -> Pecherstorfer Μ Zol ler WG -> Schewe CK Zöl lner Ν -> de Vries JX Zöl lner Ν -> Lö f f le rW Zöl lner Ν - * Schewe CK Zöl lner Ν -> Wagner DR Zöl lner Ν: Anecdotal evidence 815 Zöl lner Ν: Habent sua fata l ibel l i 937

Indexed in Current Contents and Index Medicus

Cl in Inveslig (1994) 72:1027-1029

Case Report

Glinical Investigator

© Springer-Verlag 1994

Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS U . Liegl, J.R. Bogner, F .D. Goebel

Medizinische Pol ikl in ik , K l i n i k u m Innenstadt, Univers i tä t M ü n c h e n , Pettenkoferstrasse 8a, D-80336 M ü n c h e n , Germany

Received: 26 July 1994 / Accepted: 11 August 1994

Abstract. Pentamidine is known to cause severe dysglycaemia by damaging ß-cell function of the pancreas. The exact mechanism still remains un­clear. We report the case of a 53-year-old man in ­fected wi th the human immunodeficiency virus who developed insulin-dependent permanent dia­betes mellitus 3 days after starting intravenous treatment with pentamidine for Pneumocystis carinii pneumonia. Discharged from hospital the daily need of insulin increased continuously over one year now requiring an average dose of 80 units per day. So far, a number of cases of insulin-depen­dent diabetes mellitus following pentamidine thera­py has been reported, but long-term observations are rare.

Key words: Pentamidine - Diabetes mellitus - H u ­man immunodeficiency virus

Insulin-dependent diabetes mellitus ( I D D M ) fol­lowing parenteral pentamidine therapy in patients wi th the acquired immune-deficient syndrome (AIDS) has been described as a rare adverse event of the drug in a number of cases. Lit t le is known about the exact mechanism of action, and there are no reports of long-term follow-up except one case with a follow-up of 8 months after the onset of diabetes mellitus. We report the case of a patient wi th A I D S developing I D D M after pentamidine treatment. His need of insulin increased continu­ously over 1 year.

Case report

A 53-year-old white man wi th known human i m ­munodeficiency virus (HIV) infection since 1985

Abbreviations: A I D S = acquired immune-deficiency syndrome; H I V = human immunodeficiency virus; I D D M = insulin-de­pendent diabetes mellitus Correspondence to: U . Liegl

(current CD4 cell count 40/mm 3 ) presented wi th fever, dyspnea, and cough requiring hospital ad­mission. Physical examination revealed a patient in reduced general health wi th a respiration rate of 42/min and a heart rate of 104/min. Blood gas anal­ysis showed severe hypoxemia ( p 0 2 49.4 mmHg). Life-threatening Pneumocystitis pneumonia was suspected although the patient had used pen­tamidine inhalations for P. carinii prophylaxis dur­ing the past 6 months wi th very good compliance. After demonstration of P. carinii in the bron-chioalveolar lavage fluid high-dose intravenous cotrimoxazole therapy was started. The patient de­veloped severe skin rash after 1 day, and cotrimox­azole was therefore replaced by intravenous pen­tamidine (4mg/kg). Methylprednisolone (100 mg/ day) was added for 2 days to improve hypoxia. Wi th in 2 weeks the pneumonia resolved; pen­tamidine was given for a total of 15 days.

After 3 days of pentamidine therapy asymp­tomatic hyperglycemia occurred, wi th serum glu­cose levels ranging up to 520 mg/dl requiring in­sulin therapy. Before pentamidine administration routine blood glucose tests had been normal. After discontinuation of pentamidine the hyperglycemia persisted, requiring increasing doses of insulin. The patient was discharged from hospital wi th an aver­age daily dose of 16 U insulin per day. Wi th in 12 months later the average daily dose had increased to 70 U (Fig. 1). N o other risk factors for the devel­opment of diabetes mellitus were found. There was no family history of diabetes mellitus, hemoglobin A l c was within the normal range at the onset of hyperglycemia, and test results for antibodies against islet cells were negative. Low C peptide lev­els (1.5 ng/dl postprandial) indicated ß-cell dys­function.

Two weeks after discontinuation of pen­tamidine the patient had an episode of nausea and vomit ing lasting for several days, accompanied by an increase in serum lipase to 490 U / l , serum amy­lase remaining wi th in normal range. Over a period

1028

blood glucose / mg/dl d a i | y n e e d ° ' i n s u l i n / I U

0 -] r , , , , , , , r T , , , , r , , f- 20

oug. sept. oc l . nov. dec. Jan. feb. morch opril

Fig. 1. Postprandial blood glucose levels in the outpatient clinic and daily requirement of insulin over 9 months after discontinu­at ion of pentamidine

of 5 months lipase levels gradually returned to nor­mal without further specific therapy.

Discussion

Pentamidine, an aromatic diamidine wi th antipro­tozoal activity is used in the treatment of try­panosomiasis, leishmaniasis, and most importantly P. carinii pneumonia. It appears to affect oxydative phosphorylation, nucleic acid synthesis, glucose metabolism, and folic acid synthesis, but the exact mechanism of its antiprotozoal effect is not yet known [5]. The drug can be administered by inhala­tion, intramuscularly, and intravenously. Its vol­ume of distribution is extremely high (3 1/kg) while the plasma half-life is very short (a few minutes) [12]. Experimental animal models show a high con­centration of the drug in kidneys, liver, and lungs but also in other organs such as the pancreas after intravenous administration [6]. Seven days later the concentration of the drug in the organs remains almost unchanged [13]. Pentamidine is largely elim­inated by renal excretion; a small proport ion is also eliminated by liver and salivary glands.

Side effects of the drug are common, the most frequent of which are hypotension and hypo­glycemia, the latter occurring in up to 26% of H I V -infected patients treated by intravenous pen­tamidine [7]. Persistent I D D M following pen­tamidine has been reported in about 25 cases so far [3, 4, 7, 8, 10, 14]. There are 12 case reports from India on patients treated for kala-azar [8]. Eleven of these developed I D D M , one of whom could be suf­ficiently treated by oral antidiabetics. A l l of these patients were followed up over the next 2-5 years

and the diabetes persisted. The other reported cases of pentamidine-induced diabetes mellitus are A I D S patients treated wi th pentamidine for P. carinii pneumonia. There is only one case of non-insulin-dependent diabetes mellitus caused by pentamidine [1]. While this was the case with the shortest dura­t ion of therapy (9 days), the one wi th the longest duration (21 days) was accompanied by severe pan­creatitis [14]. These clinical observations support the results of animal models in which the toxicity of pentamidine on the ß-cells of the pancreas ap­peared time dependent, dose dependent, and irre­versible [2, 3, 11]. Renal insufficiency has been shown to increase toxicity, but liver damage does not seem to affect toxicity of the drug [2]. A similar effect was observed after the administration of streptozotocin, alloxan, and certain rodenticides [9]. Histological examination of the pancreas was performed in one human who had developed dia­betes mellitus after pentamidine treatment [14] and in rats exposed to pentamidine [2,11]. Morpholog­ical changes differed from those found in the pan­creas exposed to other toxic agents or in the pan­creas of patients suffering from I D D M . The pan­creas showed a decrease in ß-cells and an increase in Α-cells without ß-cell necrosis or lymphocytic infiltration. There is no further information about the exact mechanism of action of the drug's damag­ing potential to ß-cells.

The case described here emphasizes the toxicity of pentamidine to the pancreas. In this patient we found a slowly increasing need of insulin over 1 year after pentamidine therapy which cannot be explained by dietary failure. Although the drug is known for its persisting and extremly high concen­trations in almost all organs [10], it remains unclear how pentamidine can cause an increase of need of insulin even months after discontinuation of thera­py. Further investigations must be performed to ascertain the exact mechanism of action of pen­tamidine's high toxicity.

References

1. Abour izk N N , Lyons RW, Madden G M (1993) Transient state of N T D D M in a patient w i th A I D S . Diabetes Care 16:931-933

2. Assan R, Assan D , Delaby J, Debussche X , Toublanc Μ (1993) Pentamidine-induced dysglycaemia: experimental models in the rat. Diabetes Metab 19:262-272

3. Boi l lo t D , Veld Ρ in't , Sai P, Feutren G, Gepts W, Assan R (1985) Functional and morphological modifications induced in rat islets by pentamidine and other diamidines in vi t ro . Diabetologica 28:359-364

4. Collins RJ, Pien F D , Houk J H (1989) Case report: Insulin-dependent diabetes mellitus associated wi th pentamidine. A m J Med Sei 297:174-175

1029

5. Goa L G , Campoli-Richards D M (1987) Pentamidine Isethionate. A review of its antiprotozoal activity, phar-makokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33:242-258

6. Hauser L , Sheehan P, Simpkins Η (1991) Pancreatic patholo­gy in pentamidine-induced diabetes in acquired immunode­ficiency syndrome patients. H u m Pathol 22:926-929

7. Herchline T E , Plouffe JF, Para M F (1991) Diabetes mellitus presenting wi th ketoacidosis fol lowing pentamidine therapy in patients w i th acquired immunodeficiency syndrome. J I n ­fect 22:41-44

8. Jha T K , Sharma V K (1984) Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med 78:252-253

9. Karam JH, Lewi t t PA, Young CW, Nour la in RE, Frankel BJ, Fujia H , Freedman Z R , Grodsky G M (1980) I n -sulinopenic diabetes after rodenticide (Vacor) ingestion: a unique model of acquired diabetes in man. Diabetes 29 :971-978

10. Lambertus M W , M u r t h y A R , Nagami Ρ, Goetz M B (1988) Diabetic ketoacidosis fol lowing pentamidine therapy in a patient wi th the aquired immunodeficiency syndrome. 149:602-604

l l . S a i P, Boi l lo t D , Boitard C, Debray-Sachs M , Reach G, Assan R (1983) Pentamidine, a new diabetogenic drug in laboratory rodents. Diabetologica 25:418-^23

12. Terlinden R, R ö m e r A (1990) Pharmakokinet ik und Toxikokinet ik von Pentamidin in der Ratte nach intra­venöser und Aerosolgabe. M e d K l i n 85:245-247

13. Wingen F (1990) Autoradiographische Untersuchung der Organverteilung von 14C-Pentamidin nach in t ravenöse r und inhalativer Verabreichung an Ratten. Med K l i n 85:236-244

14. Wood G, Hogan P, Wetzig N , Whi tby Μ (1991) Survival from pentamidine induced pancreatitis and diabetes mell i ­tus. Aust N Z J M e d 21:341-342

Subject Index of Volume 72

acetazolamide 1025 acetylcholine 262 acetylcholinesterase 262 acid 12 α-1 acid g lycoprote in 1012 acidity, buffered 14 acidity, gastric 12 acne vulgaris 1086 acquired hyperostosis syndrome 4 A C T H 481 A C T H secretion, ectopic 887 act ivator p ro te in 1 925 acute phase react ion 1007 acute phase response 1012 acutephase response 843 acyl coenzyme A cholesterol

acyltransferase 639 adenine phosphoribosyl transferase

( A P R T ) , deficiency 550 adenoma 979 adenoma, hypophyseal 481 adhesion molecules 598 adipose tissue, human 94 adrenalectomy 979 adrenoceptor subtypes 55 adrenocor t ico t ropin 56 afferent C fibers 65 af ibr inogenemia 395 agranulocytosis 390 A I D S 1, 10,50, 111, 122,221,283,288,

417, 850,878, 1020, 1041 air po l lu t ion 215 airway resistance, total 269 alanine : glyoxylate aminotransferase 1,

peroxisomal enzyme 725 a lbumin excret ion, ur inary 961 alcoholism 200 aldosterone 177, 385, 979 aldosteronism 874 - p r i m a r y 979 alkal ine phosphatase 448 a lka l in iza t ion , cytosolic 817 alkalosis, hypokalemic 874 al loantigen 715 allograft reject ion 715,1007 a l lohydroxycot in ine 193 a l lopur ino l 1071, 1076 A l p o r t ' s syndrome 728 alveolar macrophage 269 Alzhe imer ' s disease 196, 489 A m a n i t a 794 ambula tory b lood pressure measurement

864 ami lo r ide 695 amines, aromatic 364 aminoglu te th imide 481 a m m o n i u m , ur inary 385 amoxyci l l in-c lavulanic acid combina t ion

616 A M P , ur inary cyclic 341

amphote r ic in Β 769, 878 ß - a m y l o i d peptide precursor peptide 196 a m y l o i d , serum 843 amyloidosis 196 - p r i m a r y systemic 462 amyot roph ic lateral sclerosis 882 analgesie 65 androgen receptor 882 androgens 853 anemia 26 angina pectoris 30 ,307 ,442 angiographic, coronary 30 angiography - c o r o n a r y 442 - d ig i ta l subtract ion 592 - magnetic resonance 85 - q u a n t i t a t i v e 858 angiomatosis, baci l lary 50 angioplasty 592 - percutaneous t ransluminal 673 angiosarcoma 372 angiotensin 177,682 angiotensin ( A n g ) I I 685,874 angiotensin-convert ing enzyme 660 angiotensin-convertim* enzyme inh ib i t o r

985,961 angulat ion 138 ankle/brachial index 592, 1056 ankylos ing spondyli t is 4 ,321 an t i -HBs response 350 antibiot ics 1015 antibodies, anti-ganglioside 541 - ant i-nucleolar 541, 762 - an t i -phosphol ip id 541 - ant i-serotonin 541 - monoc lona l 525, 752 - platelet-specific monoc lona l 424 - m o n o c l o n a l 150 ant icoagulat ion 74 ant id iure t ic ho rmone 168,179 antifungal agents 920 antigen, platelet-specific 424 - thyroid-specific 788 ant ipyr ine 830 antisense 737 a , -ant i t rypsin 196 a , -ant i t rypsin deficiency 404 anxiety 233 aort ic aneurysm, abdomina l 206, 585 A P A C H E I I scores 843 aphasia 465 apheresis, low-densi ty l i pop ro te in 660 aplasia, pure red cell 1051 apo l ipopro te in 294, 580,660, 898 - A I 100 - B 100,558 - a p o l i p o p r o t e i n Β 100 944 - apo l ipopro te in B-100, famil ia l defective

1065 apol ipopro te in(a ) 558, 631

A P R T gene 550 aquaporins 698 arachnoidit is 1025 A R D S 843 arginine vasopressin 685 arrhythmias 775 ar ter ial obstructive disease, per iphera l

592 arteries, caro t id 436 - c o r o n a r y 660 arterioles, afferent 682 arteriovenous fistula 40 artery, media l cerebral 331 - p u l m o n a r y 30 ar thralgia 1048 ar thr i t i s , gouty 811 arthroostei t is , pustulot ic 4 aspergillus 920 aspirin 673 asthma therapy 772 atherogenesis 639 a theroma 858 atherosclerosis 435,558,580, 631 , 660,

858, 908, 944,951 atr ia l nat r iuret ic peptide 138,430, 685,

703 atr ial pacing 206 a t rophy, testicular 882 augment in 616 autoant ibody, an t i -neut rophi l

cytoplasmic 762 au to immune disease 1048 a u t o i m m u n i t y 788 autopsy 377 aztreonam 1015

B-cell 220 bacteria, sulfate-reducing 742 Bante r ' s syndrome 385, 874 basic fibroblast g r o w t h factor 639 Bechterew's disease 1056 betamethasonevalerate 749 bi le acids 36 bi le f lu id 316 b i l i a ry diseases, mal ignant 316 B i n s w a n g e n s disease 196 bio logy, molecular 415 b i o m o n i t o r i n g 364 biopsies, human muscle 150 biopsy, renal 462 - bone m a r r o w 462 bio therapy 525 bladder 213 bleeding, gastrointestinal 74 - u p p e r g a s t r o i n t e s t i n a l 653 b l o o d f low, extracerebral 331 - intracerebral 331 b l o o d pressure 60 ,512,961,996 - a r t e r i a l 944 - d i a s t o l i c 585

1093

body mass index 853 bone format ion , osteoblastic 1082 bone mar row 878 bone mass 1082 bra in 209 brain natriuretic peptide 430 brefeldin A 94 bromocr ip t ine 451 bronchoalveolar lavage 269 bronchodi la ta t ion 772 Brucel la melitensis 392 Brucellosis 392 Budd-Ch ia r i syndrome 883 bumetanide 692, 722

C-peptide 508, 669 C-reactive pro te in 782,843, 1007, 1012 C5a p r i m i n g 353 calcium 175.992 calcium overload 137 cal ium antagonist 864 cancer 525.619,939, 1012 - e p i d e m i o l o g y 240 - pancreatic 377 Captopril 961 carbohydrate fermenta t ion 742 carboxyhemoglobin 930 carcinogensesis, colonic 742 carcinoid, b ronchopulmonary 887 carcinoma - hepatocellular 525 cardiac valves, prosthetic 465 cardiavascular heart desease 631 cardiovascular r emode l ing 874 carnitine palmitoyltransferase 77, 957 carot id aneurysm 302 carot id arlery, in ternal 302 carot id stenosis 775 catecholamines 180,471 cauda equina syndrome 1056 caval filter devices 40 C D 4 c e l l 122,283 C D 4 lymphocyte 111,220 C D 8 + cytotoxic T-cells 321 cE-selectin 762 cell vo lume 985 cell vo lume regula t ion 817 cell , endothel ia l 908 - smooth muscle 908 - t u b u l a r 722 - adrenal cort ical 706 - bovine chromaff in 925 - c h o r i o n i c 687 - e n d o t h e l i a l 639 - macula densa 682 - mononucleated 150,225 - skeletal muscle 150 -va scu l a r 424 Centers for Disease C o n t r o l 283 cephalosporins 1015 cerebral b lood f low 775 cerebrospinal f l u id drainage 1020 chaperones, molecular 252 chemokinesis 30 chemotherapy 209,457 - c y t o t o x i c 417 chlorambuci l 277

chlore thy loc lon id ine 55 chlor ide 172 chlor ide reabsorpt ion 385 chloroquine 750 cholestasis 616 chlosterol 100 ,558,939,951 cholesteryl ester transfer p ro te in 294, 639 choline acetyltransferase 262 chromogran in A 127 chronic hepatit is Β survace antigen 1000 chronic obstruct ive p u l m o n a r v disease

269 cICam-1 762 cigarette smoke 240 Cilazapril 708 ci l iary beat frequency 215 ciprof loxacin 1015 cirrhosis 404 cis-elements 687 c la r i th romyc in 850 claudicat io, in te rmi t tens 673 c l indamycin 922 clobestasoleproprionate 749 c lon ing 692 Clostridium diff ici le 922 coagulat ion 913 cocaine 471 coenzvme A 639 C O L 4 A 5 728 colchicine 462,811 coli t is , d ivers ion 742 - u l c e r a t i v e 742 colon 381 colony-s t imula t ing 457, 713 colorectal cancer 117, 525 colorectal polyps 117 complicat ions, embol ic 465 computed tomography 465,499, 1020,

1056,1060 congestive heart failure 985 connective tissue disease 822 contrast m e d i u m 499 C O P D 269 copper 134 coronary artery bypass graft 731 coronary artery disease 100, 206, 294, 359,

430,435,858, 898, 951 coronary spasm 307 cort icosteroid 233, 749,1030 cor t icotropin-re leasing ho rmone 804,887 Cortisol 804 cortisone 701 cosmonauts 168 cotinine 192,225 cot r imoxazole 1037 cotton-wool spots, re t inal 288 creams, pharmaceut ical 870 cryoglobul inemia 1048 cryoglobul ins 46 Cushing's syndrome 481,887 cyanosis, central 359 cyclosporin 137,750, 992,1051 C Y P l A l 240 cystadenocarcinoma, mucinous 377 cytochrome c heme lyase 252 cytochrome P-450 190,240 cytokine 288,400, 525 ,711 . 713,752

cytomegalovirus 457, 1000, 1048 - ret ini t is 417 cytosol 251 cytostatic agents 749

D - d i m e r 395 D- t ryp tophan-6 lu te in iz ing hormone

releasing ho rmone 838 D 2 ( ) 830 deep vein thrombosis 40, 913 def ibr i l la tor , implantable 307 dehydra t ion 167 dehydroepiandrosterone sulfate 853 dementia 489 - mul t i - in fa rc t 196 denatur ing gradient sei electrophoresis

898 deoxycort icosterone acetate 88 der ived re laxing factors 580 dermat i t is , photosensit ive 749 desmin 150 dexamethasone 1025 - suppression test 887 diabetes insipidus, drug- induced 769 - nephrogenic 769 diabetes mel l i tus 200, 558, 800,1027 - insul in dependent 56, 494 - non-insul in dependent 494 ,572 ,961 dialysis 558,472 dialysis, ambula to ry per i toneal 558 diarrhea 167 - enterotoxigenic 742 diastolic dysfunction 874 diastolic heart func t ion , impa i red 462 diet induced thermogenesis 568 diet , gluten-free 519 d i l u t i on indicator 830 d ipyr idamole 673 discomfort , abdomina l 74 disease (rotavirus , adenovirus) , v i ra l 167 -cerebrovascu la r 775 - -modi fy ing ant i rheumat ic d rug 535 - f e t a l 794 - i n f e c t i o u s 415 d isod ium monof luorophosphate-ca lc ium

1082 disorder, chronic au to immune 822 - mo toneu ron 892 - h e m a t o l o g i c a l 939 diuret ic , potassium-sparing 695 diuretics 690, 708, 722 diver t icula , l u m b a r 1056 D N A p o l y m o r p h i s m 107 - r e p a i r 930 - sequence analysis 550 - single-strand breaks 930 D N A S E I foo tp r in t 687 dopamine 262 - m e s o l i m b i c 233 dopaminergic D A I , r e c e p t o r agonist 60 D o p p l e r sonography 331,465, 609 -pu l sed -wave 462 doxorub ic in 417 drug effects, chol inergic 512 drug in teract ion 1071,1076 dysglycaemia 1027 dys l ipoprote inemia 580, 800

1094

dysphagia 392 dyspnea, nocturnal 372

echocardiography 462 -s t ress 206 - transesophageal 206,465 eczema, atopic 400 edema 708 - res i s tan t 722 efficacy o f screening 117 elastase 269,782 elastase al-proteinase i n h i b i t o r 782,843 electrolyte balance 830 embolec tomy 465 embol i sm, cerebral 465 emphysema 269 - p u l m o n a r y 404 encephalitis, t ick-borne 399 endocardit is 922 ß - e n d o r p h i n 56,887 endothel ia l cell adhesion molecule 639 endothe l in 88 ,213 ,214 ,288 , 580,703 - receptor subtypes 213 endothelin-1 288 endothe l ium 580 -vascu l a r 88 endothel ium-dependent re laxat ion o f

vascular smooth muscle 88 endothel ium-der ived contract i le factors

580 - re laxing factor 88 - vasoconstricting factors 88 energy expendi ture 568 enterobacter 1015 enterophathy 313 eosinophil ia myalgia syndrome 541, 1060 eosinophil ic fasciitis 1060 epidoxorubic ine 209 epistaxis 46 ep i the l ium, colonic 742 Epste in-Barr virus 883 erectile dysfunction 138 erect ion, prolonged/pr iapism 138 erythema, necrolyt ic migra to ry 127 erythrocytosis 341 e ry th ropo ie t in 337,341 esophagitis 343 esophagus 343 estrogens, conjugated equine 502 ethanol 830,971 e thy l i sopropylami lor ide 985 e tomidate 481 evans 'b lue 830 ewing ra t io 996 exercise 568

fai lure, mu l t i o rgan 457 fat aspirat ion, subcutaneous 462 fatty acids 951 - l o n g - c h a i n 957 - s h o r t - c h a i n 742 fecal occult b lood test, immunochemica l

117 femoral artery, superficial 592 fenofibrate 294 fenoldopam 60 fer r i t in 26, 134

fe r t i l i ty 838 α - f e t o p r o t e i n 377 F E V 1 772 F E V 1 / V C 269 fever 782 f ibr inogen receptor 424 - s u b s t i t u t i o n 395 f ib romyalg ia syndrome 541 f ibronec t in 316 fibrosclerosis 788 fibrosis 138 f imbr ia lesion 262 f low cy tomet ry 535 f low-cy tomet r ic techniques 424 5-fluouraci l 525 flush, facial 331 fol in ic acid 525 fo l l ic le -s t imula t ing ho rmone 838,853 formylmeth ionyl - leucyl -phenyla lan ine

receptors 18 fresh frozen plasma 794 furosemide 722 F V C 772

gammopathy , monoc lona l I g M - k a p p a 46 gastric juice 12 gastric secretion 12 gastroenterit is , acute 167 gemfibroz i l 1065 G e n - H - B - V a x - D 350 gene expression 156 generalized seizures 76 genes, nuclear 251 gentamicin 922 glands, adrenal 979 g lomerulonephr i t i s 404 - id iopath ic membranous 277 - rapid ly progressive 762 glucagon 127,669 glucagonoma 127 glucocort icoids 701,782 gluconeogenesis 569 glucose 57, 569, 669 - m e t a b o l i s m 94,568 - tolerance, impa i r ed 887 glycine 725 glycocholic acid 36 glycoproteins 424 glyoxylate 725 goiter 967 gonadal funct ion 838 gonadotropin-releasing ho rmone 838 graft reject ion 609 grand mal convulsions 76 α - g r a n u l e membrane pro te in 424 granulocyte macrophage colony

s t imula t ing factor 390 granulocyte colony s t imula t ing factor 390,

417,522 granulocyte 457 - po lymorphonuc lea r 843 - n e u t r o p h i l i c 18 granulocyte-macrophage 457 granulocytopenia 417 Graves ' disease 390, 788 g r o w t h ho rmone 56 ,489 ,508 ,669 - releasing ho rmone 489,508

guanine 409 guanosine 3 ' ,5 ' -monophosphate, cvcl ic

138 gynecomastia 882,979

H l ion concentra t ion 14 hand's balanced salt so lu t ion 18, 30 haptoglobin 1012 Hashimoto ' s thyro id i t i s 788 heart 209 heart rate 512,996 heart transplant recipients,

immunosuppressed 350 heart t u m o r 372 hemangiosarcoma 372 hemapheresis 751 hematoma/ecchymosis 138 hemiparesis 302 hemiplegia 465 hemochromatosis 134 hemodialysis 424 ,430 ,472 ,558 , 1000 - in metacresol poisoning 472 -advanced-stage 754 -ear lys tage 754 -mid - s t age 754 - o n s e t 754 hemoglob in adducts 364 hemophil iacs, H I V - i n f e c t e d 122 hemoptysis 372 hemorrhage, i n t r a tumora l 448 hepar in , l ow molecular weight 913 - unfract ioned 913 hepatic lipase 100,294 hepatit is 36, 794 - Β 2 ,350,737, 1000, 1030 - B e antigen 2 - C virus infect ion 470 - chronic active 36 hepatocyte g rowth factor 558 hepatoma cell lines, human 737 hepatopathies 939 heroin 471 H G - 3 vaccine 350 h iberna t ion 731 high density l ipopro te in 100, 502, 580,

631, 639, 660, 908, 944, 951 , 1065 hippocampus, dorsal 262 histiocytosis, fatal hematophagic 457 h is tocompat ib i l i ty antigens 715 histoplasma capsulatum 878 histoplasmosis, disseminated 878 H I V 50 ,111,122, 220,283, 288, 850, 878,

1020,1027,1030,1037,1041 H I V transmission 1 Η L A class I antigens 321 H L A systems 715 H L A - B 2 7 321 H M G - C o A 558 homeostasis, f lu id-e lect rolyte 168 hormone replacement therapy 502 hormone , pa ra thyro id 341 -paraneoplas t i c 337 -vasoac t ive 685 human cort icotropin-releasing ho rmone

331 human mucosal lymphocyte ant igen 1 313 human mutS homologe 2 (gene) 619

1095

hydrochloro th iaz ide 1071,1076 hydrocort isone 749, 782, 794 hydrogen ion concentra t ion , t i t ra ted 12 3-hydroxy-3-methylg lu tary l hydroxych lo roqu ine 750 hydroxynicot ines 190 5 ' -hydroxycot in ine 190 17-hydroxyprogesterone 853 1 l ß - h y d r o x y s t e r o i d dehydrogenase 701 5-hydroxyt ryp tamine 541 5-hydroxyt ryp tamine type 3 receptors 811 5-hydroxyt ryp tamine type 1 A 451 hyperaldosteronism 979 hypercalcemia 448 hypercholes terolemia 558 ,631,639,660,

858, 898, 908, 939, 944,1065 hypereosinophi l ic syndrome 1060 hyperglycemia 800 hyper insul inemia 568, 800, 853 hvper l ip idaemia , f ami l i a l combined 100,

' 5 5 8 hyperostosis, diffuse id iopath ic skeletal 4 - sternocostoclavicular 4 hyperoxalur ia , p r i m a r y 725 hyperpara thyro id ism, p r imary 448 hyperplasia 979 hyperprolac t inemia 302 hyperreninemia 874 hypertension 60, 88,708, 729.799,800,

864,944 - por ta l 653 hypertensive crisis 60 hyper thyro id i sm 26 hyper tonic i ty 817 hyper t rophy , ventr icular 359 hypocholesterolemia 939 hypoglycemia 56 hypoka lemia 471,887 h y p o m o t i l i t y , esophageal 343 hypopi tu i ta r i sm 302 hypotha lamic-p i tu i ta r iy axis 56 hypoxemia , myocardia l 359

ifosfamide 209 I g A 519 I g E 225,400 I g G 220 I g G 519 I g M 519 i l iac veins 40 illness, generalized 939 imipenem 1015 immunoadsorption 660 Immunglobulin 220 -synthes is 225 - i n t r a v e n o u s 122,751,1051 i m m u n o m o d u l a t i o n 400 immunosuppress ion 535,1007 immuno the rapy 525, 975 indomethac in 385, 769 infections 1015 - b a c t e r i a l 122 - f u n g a l 920

in f l ammatory response syndrome 782 in format ion-memory-concen t ra t ion test

196 inh ib i t i on , therapeut ic gastric 12

inner membrane 252 insul in 508,669 - res is tance 571 - human 56 - p r o c i n e 56 intensive care uni t 843 intercel lular adhesion molecule-1 598 in ter feron 225,870, 1030 - i n t e r f e r o n - α 317 ,525 ,737 ,975 , 1030, - i n t e r f e r o n - γ 400,1041 in t e r l euk in 225 ,315 ,711 , 782, 843 - i n t e r l euk in 2 525,883,975 in te r leukin-2 receptor, soluble 494, 598 in t ima/media complex 874 intracavernous inject ion 138 intracranial pressure e lvat ion 1020 iodine in take 967 ion metabol i sm 168 i ron -b ind ing capacity 26 i ron supplementa t ion, ora l 519 ischemia, l i m b 673 - m y o c a r d i a l 359 ischemic heart disease 731 i traconazole 878,920

kala-azar 1041 Kaposi 's sarcoma 417, 1041 ketoconazole 481 kidney 168,448,692,708 - functions 472 - t r a n s p l a n t a t i o n 1000 - tubular necrosis 609 k i l l e r cells, lymphokineac t iva ted 525 - n a t u r a l 535 kinetics 1076

L-lactates 951 L D L apheresis 858 L D L receptor defects 898 leci thin : cholesterol acyltransferase 639,

951 left ventr icle 30 left ventr icular end-diastolic pressure 430 left ventr icular funct ion 442 leiomyosarcomas 381 leishamania donovan i i 1041 leukocyte 424,870, 985 - human mononuclear 985 - p o l y m o r p h o n u c l e a r 30 leukopenia 522 - dialysis-associated 424 L i - F r a u m e n i syndrome 619 l i m b girdle musular dys t rophy 409 l i n ton ba l loon 653 l i p i d d i s t r ibu t ion 944 l i p i d membranes 251 l ipids 502 l i pop ro te in 97,639, 951,1065 - l i p a s e 94 - m e t a b o l i s m 631,939 l ipopro te in (a ) 558, 580, 660, 1065 liposomes 417,1086 l i tho t r ipsy 604 l iver cirrhosis 138,572, 653 -decompensa t ed 134 l iver disease 36,1000 - f u n c t i o n 1007

- in jury 616 - tests 36 - t ransplantat ion 470 l iver in jury , hepatocellular-cholestativ

616 l o w densit iy l ipopro te in 294, 502, 558,

580, 631, 639, 660, 858, 898, 908, 944, 1065

lung cancer 156, 240 - s m a l l - c e l l 156 - n o n - s m a l l - c e l l 156 l u n g capacity, to ta l 269 l u n g funct ion 772 lupus erythematosus, systemic 749,762,

920 lu te in iz ing ho rmone 838, 853 l y m p h node abscess 1037 lymphocy te p ro l i f e ra t ion 220 lymphocy te subsets 535 lymphocytes 817,930 l y m p h o m a , intestinal 313

a2-macrog lobu l in 196 macrophage 639 magnesium 175 magnet ic resonance imaging 85 ,302 ,462 .

1020, 1056 malar ia , cerebral 598 malignancies, p r imary cardiac 372 ma lony l coenzyme A 77, 957 manganese powder 830 mann i to l 830 manomet ry , long- term 343 medica t ion , immunosuppressive 350 melanoma 975 melphalan 462, 522 meningi t is , cryptococcal 1020 meningoencephal i t is 850 mesothel ioma, mal ignant 317 metabol ic syndrome 800 metabol i sm, basal 568 - e n e r g y 568 - i n t e r m e d i a r y 568 - l i p i d 568 - postprandial 568 - w a t e r - e l e c t r o l y t e 168 5 me thy lu rap id i l 55 metastasis 209,377 methenamine silver stain 878 meth imazole 390 methylpredniso lone 1025 metyrapone 481 mic roa lbuminur i a 961 mic rob io logy 415 ß - m i c r o g l o b u l i n 321 microspheres 775 m i n i - m e n t a l state examina t ion 196 m i n i l i t h o t r i p t e r 604 M i r 168 mi tochondr i a 251,359 mi tochondr i a l hsp70 257 mi to tane 481 m i t r a l valve 922 monocyte chemoat t ractant protein-1 639,

711 mononucleosis-gastroenteri t is 1048 m o r t a l i t y , hospital 939

1096

Mul t i cen te r A I D S Cohor t Study 111 mul t ip l e myeloma 522 muscle, smooth 639 mushroom poisoning 794 mycobacer ium av ium i n t r a c e l l u l a r 850 mycobacteria, nontuberculous 850 - tube rcu los i s 107 myelofibrosis 878 myelography, lumbar 1056 myeloma 522 myocardia l infarc t ion 435, 951 myocard ium, h iberna t ing 442, 731 myofibri l logenesis 150 myopa thy metabol ic 77 myoton ic dystrophy 409,508 myotubes, ma tured 150

N-acetyl-4-amino-ant ipyr ine 830 N - a c e t y l - ß - g l u c o s a m i n i d a s e 799 n-butyrate 742 N- iOrmyl-meth ionyl - leucyl -phenyla lan ine

30 N-formyl-nor leucyl - leucyl -phenyla lanyl -

norleucyl- tyrosyl- lysine 353 N-methv l -N ' -n i t ro -N-n i t rosoguan id ine

930 N a 7 H ' an t ipor t 817 N a ' / H 4 an t ipor ter act ivi ty 985 Na-Cl cotransport 692 N a - K - A T P a s e 992 N a - K - C l cotransport 692 N A S A 168 nasal snuff 364 natr iuret ic pepi tde, type A 772 natr iuret ic peptides 179 nebul in 150 necrosis, renal cortex 499 neoplasia, mul t ip le endocrine 729 nephrit is , L E 749 - lupus 765 nephrocalcinosis 725 nephroli thiasis, a m m o n i u m urate 385 nephron, jux tamedu l l a ry 682 nephropathy, l ight-chain 522 - m e m b r a n o u s 277 nephrot ic syndrome 404, 558 nervous system, autonomic 996 neurofibromatosis 619 n e u r o n o p h a g y , X - l i n k e d recessive

bulbospinal 892 neurons, nigrostr iatal dopamine 262 neuropathy, au tonomic 200 - p e r i p h e r a l 200 - s e n s o r y 822 neuropept ide Y 685 neu t roph i l 18,782 - po lymorphonuc lear 269,353 nick translat ion 930 nicot ine 65, 94, 225, 233,512, 908, 925 - infusion 262 - t a r t r a t e 94 - i m i n i u m ions 190 nifedipine gastrointestinal therapeutic

system 864 ni t r ic oxide 88,685 nitrosamines, tobacco-specific 364 nocicept ion 65

non-ergot D2-dopamine agonist 451 non-hodgkin ' s l y m p h o m a 457 nonsmokers 512,804 nonsteroidal an t i - in f lammatorv d r u » 535,

811 noradrenal ine 685, 874 normotens ion 775 nucleotides eytosine 409 nucleus accumbens 233 nu t r i t i ona l status 754

obesity 800 obst ruct ion, r ight ventr icular ou t f low 359 octreot ide 127,653 ol igonucleot ides 737 oncogenes 156 ondansetron 811 opiate overdose 471 optha lmoplegia 302 orthostasis, active 996 osmola l i ty 172 osteomyeli t is , recurrent chronic mul t i foca l

4 osteoporosis 1082 ouabain, endogenous 706 outer membrane 252 oxalosis, systemic 725 o x i p u r i n o l 1071,1076 oxygen superoxide 18

p53 619 pain 65 pancreas 377, 1027 pancytopenia 457 panhypopi tu i ta r i sm 302 papi l loma viruses, human 619,870 paracrine interactions 682 paraprote inemia 46 parasites 1041 para thyro id 448 parkinsonism 489 parot i t i s 1037 parvovirus Β 19 1051 patients, septic 18 P E F 772 penic i l l in 794,922 pentamidine 1027 peptidase, mi tochondr i a l processing 252 percutaneous t ransluminal coronary

angioplasty 442,731 per ipheral t rans luminal angioplasty 592,

673 per iphera l vascular disease 673 p H - m e t r y , intragastric 12 pheochromocy toma 729 p h o r b o l myristate acetate 18 phosphatidylinositol-4,5-bisphosphate

353 phospholipase 843 phospholipase A 2 782 phosphol ipids 951 physical exercise 804 p i tu i ta ry hormones 804 placebo 961 plasmocytoma 883 Plasmodium falciparum 598 platelet 639,673

platelet aggregat ion 424 p la te le t -der ived g r o w t h factor 639 plexus neuropa thy , postvaccinal 399 plus maze 233 Pneumocyst is ca r in i i pneumonia 111,

1027,1037 podagra 811 p o i n t mu ta t ions 240 polycyst ic ova ry syndrome 853 po lyendoc r inopa thy , au to immune 494 polymerase cha in react ion 240,550, 898 p o l y m o r p h i s m 240 p o l y n e u r o p h a t h y 822,1060 polyposis c o l i , adenomatous 619 polysaccharide, nonstarch 742 postmenopause 502 potass ium 175,471 pravasta t in 1065 p r e a l b u m i n 1012 precarcinoconogens 240 precursor p ro te ins 252 prediabetes 494 predniso lone 277 - e x o g e n o u s 701 prednisone 462, 701 preeclampsia 799 preglucagon 127 pregnancy 794, 799 preprog lucagon 127 p r e p r o t e i n receptors 252 p r i m a r y cell cu l tu re 317 p r o e n k e p h a l i n 925 prognosis 585 progressive systemic sclerosis 343. 541 p ro l ac t i noma 451 pros tag landin Ε 385 - r e n a l 385 - E , 138 - E 2 769 p r o t e i n f o l d i n g 252 p r o t e i n kinase C 18 p r o t e i n lipase 100 p r o t e i n tyrosine kinases 713 proteinase i n h i b i t o r Ζ 404 p r o t e i n u r i a 462 p r o t h r o m b i n ac t ivat ion fragments 395 pseudohypopara thyro id i sm 341 psychological stress 804 publ ica t ions , scientific 555 p u l m o n a r y capi l la ry wedge pressure 465 p u l m o n a r y e m b o l i 40 pulsa t i l i ty index 609

rad io the rapy 838 r a n d o m m i g r a t i o n 30 ra t 775 @sprague-dawley 262 - spontaneously hypertensive 88 receptor , a m i l o r i d e 695 - n ico t in ic 262 r ecombinan t tissue-type plasminogen

ac t iva tor 465 rectoscopy 381 r ec tum 381 renal b l o o d f low 685 renal cell ca rc inoma 337,619 rena l disease 558,708,711

1097

renal fa i lure 522 - a c u t e 609,499 - dialysisdependent chronic 430 - end-stage 353,424,754 renal funct ion 685,703 renal insufficiency 277 renal microc i rcula tory func t ion 682 renal microvasculature 682 renal stone disease 550 renal tubules 698 ren in 177 renin con t ro l 687 reperfusion injury 719 residual vo lume 269 resistance 1015 - p e r i p h e r a l 60 resistive index 609 respi ra tory chain 359 respira tory quotient 568 respira tory tract 215 restenoses 673 restr ic t ing fragment length p o l y m o r p h i s m

107,453,550,898 re t ina l microangiopathic syndrome 288 re t inoblas toma (gene) 619 r e t i n o i c a c i d 1086 rhabdomyolysis 77 rhabdomyosarcomas 150 r h e u m a t o i d arthrit is 535 r h e u m a t o i d factor 535 ribosomes 251 r ibozymes 737 Riedel 's s truma 788 r i fabu t in 850 risk factor 240, 435 R N A , tissue 156 R N A - 1 , Epste in-Barr virus encoded 883 rochal imaea 50 r o x i n d o l 451

salicylic acid 749 saline infusion 817 saline, isotonic 971 salivary duct stones 604 Salyut 168 sarafotoxin 88,213 sarcoma, embryona l 209 - u n d i f f e r e n t i a t e d 209 scint igraphy, somatostatin receptor 887 sclerotherapy 653,971 self-medication 74 seminoma 838 sengstaken 653 sensorimetry, quanti tat ive sepsis 18,782 septal defect, ventr icular 359 septum, interventr icular 462 seroconversion 122 serotonin 451,541,811 serum amylo id A pro te in 1007 sex ho rmone metabol ism 751 shock 782 - wave t reatment 604 - c a r d i o g e n i c 465 sialolithiasis 604 sicca syndrome 822 signal t ransduct ion 353,713

silent ischemia 307 s i l ib in in 794 singele-strand confo rmat ion

po lymorph i sm 898 single-photon emission computed

tomography 731 Sjogren's syndrome 822 skin disease, chronic in f l ammatory 400 sleep-wake cycle 315 small intestine 313 small nerve fiber funct ion 822 smokers ' ur ine 190 smokers 269,364,804, 930 - h a b i t 512 -pass ive 364 smooth muscle, vascular 992 SMS 201-995 669 sodium 172,800,817 - f l u o r i d e 1082 - reabsorpt ion 722 somatostat in 127, 653, 669, 887 space flights, long- term 168 spinal cord 65 spinal muscular a t rophy 882 spironolactone 695, 979 Spondarthritis, pustulopsoriat ic

hyperostot ic Spondarthrit is 4 spondyloar thropathies , seronegative 321 sports 399 squamous cell carcinoma 240 standarized m o r t a l i t y ra t io 117 steroid biosynthesis inh ib i tors 481 steroid, cardiotonic 706 streptococcus mit is 922 streptococcus pneumoniae 1037 strictures 343 study, longi tud ina l 117 s tunning 731 subarachnoid hemorrhage 302 suggestibil i ty 512 sulfur d ioxide 215 superoxide anion 18 superoxide dismutase 719 superoxide p roduc t ion 353 sural nerve 65 surgery t h y r o i d 967 syncope 372

Τ cells 321 tachyar rhy thmia 307 tachycardias, hypotensive 775 T a q I R F L P 550 te icoplanin 922 terlypressin 653 testosterone 853 tetanus 399 te t ra logy o f fa l lot 359 thalamus 65 therapy, an t ib io t ic 1015 - diuret ic 985 - f ib r iono ly t i c 465 - immunosupp re s s ive 749 - r e h y d r a t i o n 167 - s u b s t i t u t i o n 395 thiazides 692 th iobarb i t a l 775 t h i o c t i c a c i d 794

thiocyanate 830 thiosulfate 830 th iourea 830 t h rombec tomy 40 t h r o m b i n act ivat ion 395 th romboembol i c , prophylaxis 913 t h r o m b o m o d u l i n 598 thrombosis 40 ,465,883 th romboxane 673 thymine 409 t h y r o i d cysts 971 t h y r o i d dysfunction 975 thyro id - s t imula t ing ho rmone 489 ,971 ,

975 - releasing ho rmone 489 thyrox ine 26 ,967 ,971 ,975 t i l t table 996 tobacco smok ing 238,930 tob ramyc in 1015 t r amado l 76 t rans-3 ' -hydroxycot inine 190 trans-activating factors 687 t ransferr in 1012 t ransforming g r o w t h factor 558, 713 transplant reject ion 715 t ransplanta t ion 715 - k i d n e y 609 - l i v e r 1007 - r e n a l 1000 - renal cadaveric 719 transport , mucoci l ia ry 215 t rauma 18 - m u l t i p l e 843 t r e t ino in 1086 t r iamcinolone 100, 294,502, 749, 944,

1065 t r i i odo thy ron ine 26 ,944,971 tr i lostane 481 t r i t o n C-100 77 t r i t o n X-100 957 T r y p s i n 957 tuberculosis, pu lmona ry 107 tubula r actions 690 tubu log lomeru la r feedback 682 t u m o r b io logy 156 - c a c h e x y 127 - cell marke r 337 - g r o w t h 127 t u m o r necrosis factor 18,94, 225, 470,

472 ,525 ,711 ,782 ,843 t u m o r suppressor genes 619 - v i r u s e s 619 -gas t ro in tes t ina l 525 - mal ignant bronchogenic 156

ul t rasound 435 ,585 ,604 ,609 - e n d o r e c t a l 381 - t h y r o i d 967,971 u remia 353 ureter, human 213 ure thra , human 55 ur ic acid 385,1071 uroli thiasis 725 - 2 ,8-dihydroxyadenine 550

vaccinat ion 350 valvular heart disease 30

1098

variceal b leed ing 653 vascular cell adhesion molecule-1 598 vascular disease 288 vascular system 85 vasculopathy, ch ron ic t ransplant 719 vasoconstr ic tor 214 vasopressin 653,698 ven t r i cu la r f i b r i l l a t i o n 307 ven t r i cu la r pac ing 775 very l o w densi t iy l i p o p r o t e i n 100,294,

502, 568, 639, 944,1065 vigi lance 512 v i t a m i n Κ 794 v o n H i p p e l - L i n d a u s y n d r o m e 619, 729

W a l d e n s t r ö m s m a c r o g l o b u l i n e m i a 46 W a l t e r reed classif ication 288 warts , genital 870 wate r 172 -channe l -co l lec t ing duct 698 - c h a n n e l s 698 - D 2 1 s O 830 - t r a n s p o r t 698 - t o t a l body 830 - t r i t i a t e d 830 Wegener ' s granulomatos is 762 weightlessness 168 w i l d type p53-act ivated f ragment 619 W i l m s ' t u m o r (gene) 619 Wilsons 's disease 134

X chromosome 728 xe roph tha lmia 822 xeros tomia 822

z idovud ine 111 zinc, ur ine 1012 zymosan ac t iva ted plasma